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Abstract 
An integrative, biochemical, genetic, and molecular biology approach utilizing 
gene manipulation, gene knock outs, plasmid based protein expression, and in vivo 
protein localization of fluorescence tagged proteins was employed to determine the 
function of an essential protein, Lst8, in TORC1 and TORC2 signaling and a previously 
uncharacterized complex, the Far3-7-8-9-10-11 complex (Far complex) in the budding 
yeast, Saccharomyces cerevisiae. Mutations in SAC7 and FAR11 suppressed lethality of 
both lst8Δ and tor2-21 mutations but not TORC1 inactivation, suggesting that the 
essential function of Lst8 is linked only to TORC2.  
Far11, a component of a six-member complex, was found to interact with Tpd3 
and Pph21, conserved components of Protein Phosphatase 2A (PP2A) via co-
immunoprecipitation. Mutations in FAR11 and RTS1, which encodes a PP2A regulatory 
B subunit, restore phosphorylation to the TORC2 substrate Slm1 in a tor2-21 mutant. 
These data suggest that TORC2 signaling is antagonized by Far11-dependent PP2A 
activity.  
To characterize the assembly of the Far complex in vivo, intracellular localization 
of the Far complex was examined by fluorescence microscopy. It was found that the Far 
 xv 
 
complex localizes to the endoplasmic reticulum (ER). The data show that Far9 and 
Far10 are tail-anchored proteins that localize to the ER first and recruit a Far8-Far7-Far3 
pre-complex. Far11 is found at the ER only when all other Far proteins are assembled at 
the ER. Surprisingly, ER localization is required for the Far Complex’s role TORC2 
signaling because deletion of the tail-anchor domain of Far9 results in partial bypass of 
the tor2-21 mutant growth defect at 37 ˚C.  
 
 
 
 
 
 
 
 
 
Keywords: Lst8; Far11; Yeast; protein phosphatase 2A; rapamycin; TOR signaling 
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CHAPTER I.  INTRODUCTION 
1.1. Saccharomyces cerevisiae: Baker’s Yeast as a Model Organism 
Saccharomyces cerevisiae or Baker’s yeast is one of the most studied eukaryotes. 
From its applications in baking and brewing to its versatility as a model organism in the 
laboratory, the study of this organism continues to produce valuable information 
relevant to both the scientific/medical community and breweries alike. In 1996, the 
entire genome, approximately 12000bp or 6000 genes was sequenced (46). The following 
year, Botstein et al. estimated that 31% of all yeast gene products had mammalian 
counterparts, a number which they felt was actually much greater due to the fact that 
the majority of the mammalian genome had yet to be sequenced (18). This sparked the 
use of Baker’s yeast as a model organism for the studies of mammalian pathways.  
Yeast have the ability to exist as either diploids (2N) or haploids (1N) and can 
reproduce both sexually and asexually (6). Figure 1 summarizes the yeast cell cycle. 
Baker’s yeast reproduce asexually through the mitotic cell cycle, a highly regulated 
process also known as budding where a small bud forms on the parent cell. Briefly, 
during progression through the mitotic cell cycle, genetic information is replicated 
during the S and G2 phase. Replicated DNA, organelles, and cytoplasm are then 
divided amongst the parent and daughter cell and the daughter cell grows until its size 
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approximately matches the parent cell during the M phase. At the end of the M phase, 
cytokinesis splits the two into separate cells and both cells enter G1 phase. Cell cycle 
progression is highly regulated and many signaling pathways target cell cycle 
progression by inhibiting progression from G1 to S phase to prevent cell proliferation in 
response to various signaling cues. 
Haploid lab strains characteristically produce one of two mating pheromones: a-
factor, and α-factor. a-type yeast cells produce a-factor and α-type cells produce α-
factor. Each type cell has receptors for the opposite type factor such that when cells are 
in the presence of mating factor of the opposite type, cell cycle progression is halted at 
the G1 phase and polarized cell growth begins in the direction of the mating factor. 
Polarized cell growth continues until two cells of opposite mating type are able to fuse 
forming a new diploid cell (6). 
The fate of diploid cells depends on nutrient availability. Under rich growth 
conditions, diploid cells will continue through the mitotic cell cycle. However, under 
stressful or nutrient deplete conditions diploid cells will switch to sexual reproduction 
or meiosis to produce new haploid cells or spores by undergoing sporulation (6, 111). 
Yeast geneticists widely take advantage of this unique versatility in ploidy to create 
specific mutant cell lines by mating haploids of certain genotypes, sporulating the 
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resulting diploid and selecting spores that contain the desired genotypes. This makes 
yeast an invaluable tool for genetic studies of conserved pathways whereby in other 
organisms necessary mutants are unobtainable. Yeast have the capacity to contain 
genetic information on plasmids. The power of yeast genetics becomes apparent when 
essential genes are expressed on plasmids and transformed into diploid cells 
heterozygous for the essential gene. When these cells are sporulated, it is possible to 
obtain a haploid strain that lacks the essential gene in the genome yet are sustained due 
to the presence of the essential gene on the plasmid. These strains are then able to be 
manipulated to identify mutations that allow for loss of the plasmid and by association 
the essential gene. 
Furthermore, the usefulness of Baker’s yeast as a single cellular model organism 
parallels that of bacterial systems in that yeast cells can be grown in a matter of days, 
are non-pathogenic, easily amplifiable and able to be cryogenically stored indefinitely. 
These characteristics paired with its conservation of eukaryotic system make Baker’s 
yeast a highly convenient model organism. 
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Figure 1.  Stages of the yeast life cycle.   
Schematic diagram of the haploid and diploid life cycles of budding yeast. 
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1.2. The TOR Signaling Pathway 
Target of rapamycin (TOR) is a phosphatidylinositol kinase-related protein 
kinase (PIKK) that controls eukaryotic cell growth and proliferation in response to 
nutrient conditions (40, 62, 125). TOR, first identified in yeast and subsequently in 
mammalian cells, is inhibited by the complex of rapamycin, an immunosuppressant 
macrolide, and the immunophilin FKBP12, a peptidylprolyl cis-trans isomerase. 
Rapamycin, by inhibiting TOR, serves as an immunosuppressant, an inhibitor of 
restenosis, and a potential chemotherapeutic agent for cancer treatment (99, 104, 107, 
116, 125).   
1.2.1 The TOR Complexes 
TORs are large protein kinases (~280 kD) conserved in most, if not all, eukaryotes 
(125). Fungal species may possess two TOR kinases while higher eukaryotes possess 
only one. The TOR kinase consists of HEAT (Huntington, Elongation factor 3, protein 
phosphatase 2A, TOR1) repeats at the amino-terminal half of the protein, a FAT (FRAP, 
ATM, TTRAP) domain, an FRB (FKBP12-rapamycin binding) domain, a kinase domain, 
and an FATC domain (Fig. 2). The TOR kinase exists in multi-protein complexes, which 
have been purified in yeast and mammals. There exist two distinctive TOR kinase 
complexes in yeast: a rapamycin-sensitive TOR Complex 1 (TORC1) (consisting of Tor1 
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or Tor2, Lst8, Kog1, and Tco89) and a rapamycin-insensitive TOR Complex 2 (TORC2) 
(consisting of Tor2, Lst8, Avo1, Avo2, Avo3, and Bit61) (Fig. 2A and 2B) (81, 94, 121). Of 
the two branches TORC1 has been studied the most. Both complexes are partially 
conserved in mammals: mTORC1 complex contains raptor, a Kog1 ortholog; mTORC2 
contains rictor and mSin1, orthologs of yeast Avo3 and Avo1, respectively. GβL, the 
mammalian ortholog of yeast Lst8, exists in both mTORC1 and mTORC2 (41, 63, 64, 69, 
70, 98, 130). TOR is a central controller of cell growth in yeast by sensing and 
responding to changes in nutrient conditions (100). Physiological processes regulated 
by TOR are also partially conserved: TORC1/mTORC1 positively regulates anabolic 
processes including ribosome biogenesis and protein translation while inhibiting 
catabolic processes such as autophagy; TORC2/mTORC2 is involved in the organization 
of the actin cytoskeleton (Fig. 2) (11, 57, 58, 83, 84, 102, 103, 117, 125, 133).  
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Figure 2.  TOR Complex 1 (TORC1) and TOR Complex 2 (TORC2) of budding yeast.   
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 (A) TORC1 is consisted of Tor1 or Tor2, Kog1, Lst8, and Tco89. Depicted are domains 
of TOR, HEAT, FAT, FRB, kinase, and FATC. Rapamycin, in complex with FKBP12 (not 
shown), inhibits TOR through its binding to the FRB domain of TOR. TORC1 senses 
nutrient signals and promotes anabolic processes including ribosome biogenesis, 
protein translation, and nutrient transport while inhibiting catabolic processes like 
autophagy, stress-responsive transcription, and glycogen synthesis.  
(B) TORC2 is consisted of Tor2p, Lst8p, Avo1-3p, and Bit61p. TORC2 is involved in the 
regulation of the actin cytoskeleton. 
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1.2.2 TORC2 signaling and the Cell Wall Integrity Pathway 
All eukaryotic cells must balance the regulation of several important pathways in 
order to maintain a healthy state of growth. In yeast, one example of such is the 
regulation of the Cell Wall Integrity (CWI) Pathway. Integrity of the yeast cell wall is 
required for cell shape and stability as well as budding to produce daughter cells to 
ensure proliferation of the cell line (26, 29) Constant remodeling of the cell enables cell 
expansion during normal vegetative growth and morphology changes in response to 
mating pheromone (54). Because water can freely enter cells, turgor pressure can build 
in the cell. The cell wall must be rigid in some areas while pliable in others to enable the 
cell to take on shapes other than perfect spheres and not rupture in hypo-osmotic 
environments. For this, an internal actin cytoskeleton is utilized to direct cell wall 
expansion to a particular area (32). The CWI pathway is a signaling pathway in which 
signals received from a family of cell surface sensors are transmitted to a Rho1/2p 
GTPase switch, comprised of the Rho GTPases,  Rho1 and Rho2, the Rho GDP-GTP 
exchange factors (GEF) Rom2 and Tus1, and the Rho GTPase activating protein (Rho 
GAP) Sac7 (11, 57, 58, 102, 130) (Fig. 3). Activated Rho1/2 transmit this signal by 
activating the Pkc1-activated mitogen-activated protein (MAP) kinase cascade (56). The 
Pkc1-activated MAP cascade consists of Pkc1, Bck1, redundant Mkk1 and Mkk2, and 
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Slt2. In the current model, activated Pkc1 phosphorylates Bck1 which phosphorylates 
Mkk1 and Mkk2 that in turn phosphorylate Slt2. Phosphorylated Slt2 then 
phosphorylates downstream targets to activate synthesis of the cell wall (reviewed in 
(43)). While the CWI Pathway has been extensively characterized there is some dispute 
over whether it functions in a parallel or a linear pathway with the Target of Rapamycin 
(TOR) signaling pathway.   
The rapamycin-insensitive TORC2 mediates organization of the actin 
cytoskeleton through activation of the same Rho1/2 GTPase switch as in the CWI 
pathway. How TORC2 signals to the Rho1/2 GTPase switch is not well understood and 
might involve three recently identified TORC2 substrates, Slm1/2 and Ypk2 (5, 37). 
Activation of Rho1 and the Pck1-Bck1-Mkk1/2-Mpk1cell integrity pathway can restore 
cell growth to tor2 mutant cells (11, 57, 58, 102). Cell wall defects, induced by treating 
cells with small amounts of SDS or by mutations compromising cell wall synthesis can 
also suppress a tor2 mutation possibly by activating cell wall integrity signaling via 
Rho1, which requires both Rom2 and Tus1, another GEF for Rho1 (101). Therefore, 
TORC2 signaling and the CWI pathway likely converge to regulate organization of the 
actin cytoskeleton (Fig. 4). Apart from its role in organizing the cytoskeleton, it is not 
known what other pathways this complex may regulate, and no one knows what 
regulates TORC2 signaling. 
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Figure 3.  Diagram of the Cell Wall Integrity pathway.   
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Figure 4.  The TORC2 signaling pathway converges with the CWI pathway.   
TORC2 is involved in the regulation of the actin cytoskeleton through the activation of a 
Rho1/2 GTPase switch, consisted of the Rho GTPases,  Rho1 and Rho2, the Rho GDP-
GTP exchange factor (Rho GEF) Rom2, and the Rho GTPase activating protein (Rho 
GAP) Sac7. TORC2 may signal to the Rho1/2 GTPase switch via phosphorylation of 
Slm1/2 and Ypk2. 
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1.2.3 Lst8: an essential component of both TOR complexes 
Lst8 is essential for cell viability in S. cerevisiae (97). It is still unknown whether 
the essential function of Lst8 is linked to TORC1, TORC2, or both. In TORC2, Lst8 binds 
to the C-terminal kinase domain of Tor2, independent of Avo1/2/3, and Lst8 depletion 
destabilizes interaction between Tor2 and Avo2 or Avo3 (126). Lst8 is also required for 
full Tor2 kinase activity in vitro and its depletion leads to defective polarization of the 
actin cytoskeleton similar to tor2 mutations (81, 126). However, although over-
expression of MSS4 (encoding a PI-4-P 5 kinase), RHO2, ROM2, or members of the cell 
integrity pathway, PKC1, MKK1, or BCK1 suppresses both tor2 temperature-sensitive 
(tor2-21) and avo1 mutations (57, 58, 81), these suppressors have been reported to be 
unable to suppress an lst8 mutation (81), raising the question whether the essential 
function of Lst8 is linked to TORC2. On the other hand, the role of Lst8 in TORC1 is also 
largely unknown.  
1.2.4 Cellular localization of the TOR complexes 
Earlier studies on the localization of components of the TOR complexes led to a 
variety of conclusions about the identity of membranes with which components of the 
TOR complexes are associated (23, 25, 72, 94, 121). What was clear from these studies is 
that TORC1 and TORC2 associate with membrane structures. Several recent reports on 
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the localization of TOR components suggest that TORC2 is predominantly found as 
punctate structures at the plasma membrane while TORC1 dynamically associates with 
the vacuolar membrane (3). Discrepancy of these localization data may be partly due to 
dynamic associations of TORC1 and TORC2 with different membrane structures in 
response to changes in nutrient conditions.       
1.3 Rapamycin and its clinical applications 
The namesake of TOR signaling, rapamycin, is a macrolide that was first 
discovered in 1975 on the island of Rapa Nui, Easter Island. Rapamycin, pictured in 
Figure 5, was originally identified as an antifungal produced by the bacterium 
Streptomyces hygroscopicus mainly against Candida albicans, Microsporum gypseum and 
Trichophyton granulosum (120). It was later found to have immunosuppressive and 
antiproliferative properties and this is its major use today. Rapamycin acts as an 
immunosuppressive agent by inhibiting the response to interleukin 2 (IL-2), preventing 
activation of T and B cells (86). Once inside the cell, rapamycin binds to cytosolic 
FKBP12, encoded for in yeast by the gene FPR1, which then binds to the FRB domain of 
the Tor kinases in TORC1. For reasons unknown, rapamycin-FKBP12 does not inhibit 
TORC2, possibly due to inability to bind to the FRB domain of the Tor kinase in this 
complex (81). 
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The immunosuppressant rapamycin marketed under the name Sirolimus or 
Rapamune by Pfiser, has low toxicity towards kidneys due to its mechanism of action 
making it useful to treat patients with kidney transplants to avoid transplant rejection. 
However, since rapamycin also has antiproliferative effects, a side effect is impaired 
wound healing; therefore, it is typically not administered until several weeks after 
surgery (86). Another clinical use for rapamycin takes advantage of its antiproliferative 
property to prevent restenosis or re-narrowing of blood vessels in patients who 
received coronary stents coated with rapamycin polymer. The polymer coating allows 
for slow release of the drug to prevent restenosis over time (118). 
Renal transplant patients are at a high risk for developing Kaposi’s sarcomas 
because treatment with immunosuppressants after surgery can weaken the immune 
system that normally combat the formation of this type of tumor. Because rapamycin 
inhibited the progression of dermal Kaposi’s sarcomas in patients who had renal 
transplants, it is currently being investigated as an anticancer drug (112). For example, 
derivatives of rapamycin such as temsirolimus and everolimus are being tested for their 
effects on cancers such as glioblastoma multiforme and mantle cell lymphoma (44, 95). 
Combining doxorubicin and rapamycin is also being studied in mice to treat cancers 
that become resistant to chemotherapeutic drugs like doxorubicin due to increased Akt 
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signaling. Rapamycin is proposed to block Akt signaling rendering these cells sensitive 
to chemotherapy once again (114, 123).  
Rapamycin has also shown promise in treating an array of other disorders 
including autism and Alzheimer’s in a mouse model as well tuberous sclerosis complex 
in clinical trials (35, 110). It is being investigated in HIV, autosomal dominant polycystic 
kidney disease, and progeria, a rare aging disorder that accelerates the aging process 
typically leading to an early death in patients’ teenage years (13, 31, 91). Rapamycin 
treatment mimics nutrient starvation and leads to an increase in lifespan in both yeast 
and mouse models however this use is not recommended for humans due to its toxicity 
at high doses (55, 92). The variety of applications for rapamycin stresses the importance 
of TOR signaling. Yet, much remains to be understood about this signaling pathway. 
Therefore, the study of TOR signaling particularly the lesser understood TORC2 
signaling branch could uncover novel therapeutic targets for the treatment of these 
diseases and others yet to be linked to TOR signaling.  
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Figure 5.  The structure of rapamycin.   
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1.4 Specific Goals 
Many studies on the TOR signaling pathway have provided invaluable insights 
into the regulation and function of this pathway. While TOR signaling is an extensively 
studied pathway, the majority of studies done were on the TORC1 signaling branch. 
Much remains unknown about the regulation and possible novel functions of the 
TORC2 signaling branch. Besides Tor2, Lst8 is the only other essential component of 
both TOR signaling complexes. I have addressed two questions. First, the function of 
Lst8 in these two complexes is unknown and whether the essential function of Lst8 is 
through its action in TORC1 or TORC2 or both remains a mystery. Solving this mystery 
could provide insights into the essential function of Lst8 in TOR signaling. It is not 
possible to study the effect of losing an essential gene because cells will die in the 
absence of that gene product. Therefore, I addressed the following question: Are there 
mutations that will allow cells to survive without Lst8? Identification of such mutants 
would allow further studies to be performed on the mutants to address the first 
question. Second, identification of such mutants could present novel regulators of TOR 
signaling. If they exist, how do Lst8 bypass mutants enable cells to survive without 
Lst8? Answering this question could greatly expand the current knowledge of this 
signaling pathway and could even link pathways to TOR signaling that were not 
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known to be involved before, providing possible novel therapeutic targets for 
regulating this pathway in many of the associated diseases. 
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CHAPTER 2.  
TORC2 SIGNALING IS ANTAGONIZED BY  
PROTEIN PHOSPHATASE 2A AND THE  
FAR3-7-8-9-10-11 COMPLEX 
2.1. Summary 
The target of rapamycin (TOR) kinase, a central regulator of eukaryotic cell 
growth, exists in two essential, yet distinct TOR kinase complexes in the budding yeast 
Saccharomyces cerevisiae: rapamycin-sensitive TORC1 and rapamycin-insensitive TORC2. 
Lst8, a component of both TOR complexes, is essential for cell viability. However, it is 
unclear whether the essential function of Lst8 is linked to TORC1, TORC2, or both. To 
that end, I carried out a genetic screen to isolate lst8 deletion suppressor mutants. Here I 
report that mutations in SAC7 and FAR11 suppress lethality of lst8Δ and TORC2-
deficient (tor2-21) mutations but not TORC1 inactivation, suggesting that the essential 
function of Lst8 is linked only to TORC2. More importantly, characterization of lst8Δ 
bypass mutants reveals a role for Protein Phosphatase 2A (PP2A) in the regulation of 
TORC2 signaling. I show that Far11, a member of the Far3-7-8-9-10-11 complex 
involved in pheromone induced cell cycle arrest,  interacts with Tpd3 and Pph21, 
conserved components of PP2A, and deletions of components of the Far3-7-8-9-10-11 
complex and PP2A  rescue growth defects in lst8Δ and tor2-21 mutants. Additionally, 
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loss of the regulatory B’ subunit of PP2A Rts1 or Far11 restores phosphorylation to the 
TORC2 substrate Slm1 in a tor2-21 mutant. Mammalian Far11 orthologs, FAM40A/B, 
exist in a complex with PP2A known as STRIPAK, suggesting conserved functional 
association of PP2A and Far11. Antagonism of TORC2 signaling by PP2A-Far11 
represents a novel regulatory mechanism for controlling spatial cell growth of yeast.  
 
2.2. Introduction 
The target of rapamycin (TOR) kinase is a phosphatidylinositol kinase-related 
protein kinase that controls eukaryotic cell growth and proliferation in response to 
nutrient conditions (62, 125, 132). The TOR kinase is inhibited by the complex of 
rapamycin and Fpr1, a peptidyl-prolyl cis-trans isomerase. The TOR kinase is conserved 
in eukaryotes. Unlike fungal species, which may possess two TOR kinases, higher 
eukaryotes such as humans possess only one. The TOR kinase exists in multi-protein 
complexes, which have been purified from many different eukaryotic systems. There 
exist two distinct TOR kinase complexes. In yeast, rapamycin-sensitive TORC1 consists 
of Tor1 or Tor2, Lst8, Kog1, and Tco89, and rapamycin-insensitive TORC2 consists of 
Tor2, Lst8, Avo1, Avo2, Avo3, and Bit61 (81, 94, 121). Both complexes are partially 
conserved in mammals: mTORC1 contains the yeast Kog1 ortholog raptor, while 
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mTORC2 contains mSin1 and rictor, orthologs of yeast Avo1 and Avo3, respectively; 
GβL, the ortholog of yeast Lst8, exists in both mTORC1 and mTORC2 (132).  
 TOR  regulates cell growth by sensing and responding to changes in nutrient 
conditions (100). TORC1 has an essential function involving the regulation of cell 
growth that is carried out when either Tor1 or Tor2 is in the complex. Under favorable 
growth conditions, TORC1 promotes cell growth by maintaining robust ribosome 
biogenesis (83, 84, 133). When TORC1 is inactive, there is a dramatic down-regulation of 
general protein translation, an up-regulation of autophagy, accumulation of the storage 
carbohydrate glycogen, increased sorting and turnover of amino acid permeases, and 
activation of stress-responsive transcription factors via nuclear translocation (125). TOR 
inhibition via rapamycin treatment activates a subset of stress-responsive transcription 
factors (8, 22, 25, 27, 106). Rapamycin treatment can also lead to reduced gene 
expression, including those encoding ribosomal proteins (RP) (125). 
TORC2 has a separate essential function that is Tor2-specific, which involves cell 
cycle-dependent polarization of the actin cytoskeleton (28). TORC2 mediates the 
organization of the actin cytoskeleton through the activation of a Rho1/2p GTPase 
switch, comprised of the Rho GTPases,  Rho1 and Rho2, the Rho GDP-GTP exchange 
factor Rom2, and the Rho GTPase activating protein Sac7. Activated GTP-bound Rho1 
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activates Pkc1, which activates the cell wall integrity pathway MAP kinase cascade, 
Bck1-Mkk1/2-Mpk1. Activation of Rho1 and the cell wall integrity pathway restores cell 
growth and actin polarization to tor2 mutant cells. sac7 mutations suppress TORC2-
deficiency by increasing the levels of GTP-bound Rho1. How TORC2 mediates the 
organization of the actin cytoskeleton is unclear and might involve three TORC2 
substrates: Slm1, Slm2 and Ypk2 (4, 5, 37, 66, 115).  
Lst8 is essential for cell viability in S. cerevisiae (97). It is unknown whether the 
essential function of Lst8 is linked to TORC1, TORC2, or both. In TORC2, Lst8 binds to 
the C-terminal kinase domain of Tor2, independent of Avo1/2/3, and Lst8 depletion 
destabilizes the interaction between Tor2 and Avo2 or Avo3 (126). Lst8 is also required 
for full Tor2 kinase activity in vitro and its depletion leads to depolarized actin 
cytoskeleton similar to tor2 mutations (81, 126). Overexpression of MSS4, encoding a 
phosphatidylinositol-4-phosphate 5-kinase, RHO1/2, ROM2, PKC1, MKK1, or BCK1 
suppresses tor2 and avo1 mutations (57, 58, 81), however, these suppressors were 
reported to be unable to suppress an lst8 mutation (81). The question remains whether 
the essential function of Lst8 is linked to TORC2, and the role of Lst8 in TORC1 is 
largely unknown.  
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Here, I provide evidence that the essential function of Lst8 is linked to TORC2, 
but not TORC1. I show that components of the Far3-7-8-9-10-11 complex, which have 
been implicated in pheromone-induced cell cycle arrest, vacuolar protein sorting, and 
cell fitness, negatively regulate TORC2 signaling. I find that Far11 interacts with protein 
phosphatase 2A and that mutations in the PP2A-Rts1 subcomplex suppress TORC2-
deficiency. I propose that the Far3-7-8-9-10-11 complex and PP2A-Rts1 antagonize 
TORC2 signaling by promoting dephosphorylation of TORC2 substrates.  
2.3. Materials and methods 
2.3.1. Strains, plasmids, and growth media and growth conditions 
Yeast strains and plasmids used in this study are listed in Table 2 and 3 or 
Appendix Table 1 and 2, respectively. Yeast cells were grown at 30 °C or 37 °C in SD 
(0.67% yeast nitrogen base plus 2% dextrose),  YNBcasD (SD medium plus 1% casamino 
acids), Ura Leu drop-out (SD plus CSM without uracil and leucine, Bio101), or YPD (1% 
yeast extract, 2% peptone, 2% dextrose) medium as indicated in the text and in the 
figure legends. For lst8Δ bypass assays, SD medium with or without 1 g/L 5-Fluroorotic 
acid was used to select for growth of cells that have lost URA3 plasmids. When 
necessary, amino acids, adenine, and/or uracil were added to the growth medium at 
standard concentrations to cover auxotrophic requirements (2).  
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2.3.2. Transposon mutagenesis 
lst8Δ mutant bypass genetic screens were conducted using transposon 
mutagenesis as described (77). Briefly, ade2Δ lst8Δ cells carrying plasmid pRS412-LST8 
were used for transposon mutagenesis; after mutagenesis, cells were plated on YPD 
medium to select for colonies which were red or sectoring indicating loss of the pRS412-
LST8 plasmid. Putative lst8Δ bypass mutants were confirmed to be recessive, single-
gene mutations using standard yeast genetic techniques. Determination of transposon 
insertion sites were carried out as described (20). Briefly, a recovery plasmid encoding 
the Ampicillin-resistance gene (AmpR) and URA3 was integrated into the transposon 
integration site of the leb1 and leb2 mutants by homologous recombination and 
transformants were selected on uracil-dropout medium. Genomic DNA was then 
isolated, digested with EcoRI and ligated with T4 DNA ligase. Ligation products were 
transformed into bacteria and AmpR transformants were selected for on LB Broth 
supplemented with ampicillin. Transposon integration sites were determined by 
sequencing of the recovered plasmids. 
2.3.3.  Northern Blotting   
Total cellular RNAs were isolated using hot phenol method as described (45). 
Cells were grown in appropriate medium to ~OD600 0.6 and collected for isolation of 
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total cellular RNA. 32P-labeled probes against RPL3, RPS6a, and ACT1 were used to 
probe mRNA immobilized on nylon membranes. PhosphorImager was used to record 
signals of the RNA transcripts. Experiments were repeated at least twice. 
2.3.4.  Cellular extract preparation, immunoblotting, and immunoprecipitation   
Total cellular protein extracts were prepared by disrupting yeast cells in 
extraction buffer (1.85N NaOH-7.5% β-mercaptoethanol) followed by precipitation with 
trichloroacetic acid (TCA) as described (129). Phosphatase treatment of total cellular 
proteins was conducted as described (79). For co-immunoprecipitation experiments, 
cellular lysates were prepared in IP buffer (50 mM Tris-HCl pH 7.6, 150 mM NaCl, 0.5% 
Triton X-100, and protease inhibitors). Cell extracts (~3 mg proteins) were incubated at 4 
°C for 1 h with anti-myc antibody (9E10, Roche), after which 30 μl of a 50% slurry of 
protein G-Sepharose (Roche) was added to each sample and the samples were further 
incubated at 4 °C for 2 h. Washed immunoprecipitates bound to the sepharose beads 
were released by boiling in 1X SDS-PAGE loading buffer. The released immune 
complexes were analyzed by Western blotting. myc- and HA-tagged proteins were 
probed with anti-myc antibody and anti-HA antibody (3F10, Roche), respectively. 
Chemiluminescence images of Western blots were captured using the Bio-Rad Chemi-
Doc photo documentation system (Bio-Rad). Experiments were repeated at least twice. 
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2.3.5. Actin staining and GFP fluorescence microscopy   
The actin cytoskeleton was visualized in rhodamine phalloidin-stained, 
formaldehyde-fixed cells, as described (2). Overnight cultures were diluted to ~OD 0.1 
and allowed to grow at 30 °C for 2 h and then switched to 37 °C for 3 h before 
formaldehyde was added to a final concentration of 3.7%. After fixing for 1 h, 1mL of 
fixed cells were collected, washed in PBS buffer and stained with rhodamine phalloidin 
conjugate (Invitrogen) and visualized by fluorescence microscopy. GFP fluorescence of 
GFP-tagged proteins was analyzed in cells grown to log phase. Fluorescence images of 
rhodamine phalloidin-labeled actin structures and GFP-tagged proteins were acquired 
with a Photometrics Coolsnap fx CCD camera and Metamorph Imaging Software and 
processed using ImageJ (NIH) and Adobe Photoshop. Experiments were repeated at 
least twice. 
2.3.6. Preparation of recombinant 6xHis-tagged Slm1   
PCR-amplified SLM1 coding sequence was cloned into the SacI and XhoI sites of 
pET24a vector (Novagen). The resultant plasmid was transformed into BL21(DE3) 
competent cells (Novagen) and expression of 6xHis-tagged Slm1 was induced by 
adding 1 mM IPTG to bacterial cultures grown at 20 °C for 16 h. Recombinant C-
terminal 6xHis-tagged Slm1 was purified under native conditions using Ni-NTA 
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agarose beads (Qiagen) as described in the product instruction manual. 14 mg Slm1-
His6 was obtained from 1 L induced culture. Experiments were repeated at least twice. 
2.3.7. In vitro kinase assay of Slm1 phosphorylation by Tor2-HA   
Yeast strains expressing 3xHA-tagged Tor2 were grown overnight to mid-log 
phase and cellular lysates were prepared in lysis buffer (50 mM Tris-HCl, pH 7.6, 150 
mM NaCl, 1% Triton X-100, and protease inhibitors) by vortexing with glass beads. Cell 
extracts (~3 mg proteins) were incubated with 100 µl protein A-agarose beads (Roche) at 
4 °C for 1 h to remove nonspecific binding proteins. Precleared cell lysates were then 
incubated with 16 μg anti-HA antibody (12CA5, Roche) for 1 h, after which 40 µL of a 
50% slurry of protein A-agarose beads was added to each sample and the samples were 
further incubated at 4 °C for 1 h. Precipitates were washed twice with 1ml lysis buffer, 
twice with 1ml wash buffer (50 mM Tris-HCl, pH 7.6, 300 mM NaCl, and protease 
inhibitors), and once with 1ml kinase buffer (20 mM Tris-HCl pH 7.6, 50 mM NaCl, 5 
mM MgCl2, 1mM PMSF). After the final wash, beads were resuspended in 25 µL of 
kinase buffer plus 1 mM dithiothreitol (DTT). The reaction was initiated by adding 25 
µL reaction mixture (kinase buffer with 1 mM DTT, 0.4 mM ATP, 5µCi of [γ-32P]-ATP 
(PerkinElmer), 5 µg recombinant Slm1-His6). After incubation for 30 minutes at 30°C, 
the reaction was terminated by adding 25ul 3x SDS gel-loading buffer (150 mM Tris-
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HCl, pH 6.8, 6% SDS, 30% glycerol, 0.3% bromophenol blue) and 8.5ul 1 M DTT and 
boiling for 4 minutes. 20 µl samples were fractionated by SDS–PAGE on 7.5% 
polyacrylamide gels in triplicate, with one dried for detecting 32P-incorporation in Slm1 
by autoradiography (Molecular PhosphorImager FX, Bio-Rad), one stained by Coomassie 
Blue for detecting 6xHis-tagged Slm1, and one processed for Western blotting for 
detecting HA-Tor2. A mock treatment experiment was conducted using anti-HA 
immunoprecipitates from cells expressing non-tagged Tor2. Experiments were repeated 
at least twice. 
2.4.  Results 
2.4.1.  Mutations in SAC7 and FAR11 suppress lethality due to an lst8Δ mutation 
To gain insights into the essential function of Lst8, I conducted a genetic screen 
to search for mutations that allow cells to survive without Lst8 by employing an ade2 
colony sectoring assay (Fig. 1D). This assay takes advantage of a buildup of purine 
precursors in the vacuole, which results in colonies that appear red in ade2 mutant cells. 
I utilized a previously constructed Tn3::lacZ::LEU2 mutagenesis library (20) to introduce 
mutations in an lst8Δ ade2Δ mutant carrying plasmid pRS412-LST8 (CEN LST8 ADE2) 
and screened for red or sectoring lst8Δ bypass (leb) mutant cells on YPD medium, which 
had lost or were in the process of losing the pRS412-LST8 plasmid. Of approximately 
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30,000 Leu+ transformants, 49 viable solid red or sectoring colonies were selected for 
further analysis. Of the 49, 11 colonies were pure red. Crossing to an ade1Δ strain 
resulted in non-complementation of the red phenotype in one of the 11 pure red 
colonies indicating that the red phenotype was due to a mutation in ADE1 and not the 
loss of the pRS412-LST8 plasmid. Whereas, crossing to an ade2Δ strain resulted in non-
complementation of the red phenotype in the remaining 10 pure red colonies indicating 
that the red phenotype is due to a mutation in ADE2 or loss of the pRS412-LST8 
plasmid. However, wild-type LST8 was found by PCR to be present in all 11 pure red 
colonies, which were deemed false positives. The remaining 38 sectoring colonies were 
analyzed similarly and the red sectoring phenotype of one was due to an ADE1 
mutation while 35 were due to mutations in ADE2. PCR genotyping confirmed the 
absence of pRS412-LST8 in the remaining two mutants, termed leb1 and leb2. In these 
two leb mutants, the lst8Δ bypass phenotype was found to co-segregate with Leu+ after 
crossing to an lst8Δ leu2 ade2Δ pRS412-LST8 strain of the opposite mating type and 
tetrads were dissected, indicating that the transposon insertion had produced the 
mutant phenotype. Figure 1A shows that, in contrast to wild-type cells, leb1 and leb2 
mutants form both red and sectoring colonies, indicating loss of the pRS412-LST8 
plasmid.   
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I identified the transposon insertion site in the leb1 and leb2 mutants by plasmid 
rescue and sequencing of the recovered plasmids as described by Burns et al. (1994) and 
summarized in Figure 1E.  The transposon insertion sites in the leb1 and leb2 mutants 
were found to be in the open reading frames of SAC7 and FAR11, respectively. 
Consistently, Figure 1B-C shows that wild-type SAC7 and FAR11 on a centromeric 
plasmid can complement leb1 and leb2 mutations, respectively. Furthermore, a sac7Δ or 
far11Δ mutation in an lst8Δ ade2Δ pRS412-LST8 strain also led to lst8Δ bypass (loss of 
pRS412-LST8 is indicated by the red colony phenotype in Figure 2A).  
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Figure 1.  Mutations in SAC7 and FAR11 bypass lst8Δ.  
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Figure 1 (cont.)  
(A) Isolation of lst8Δ bypass (leb) mutants using ade2-based colony sectoring assay. 
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cells carrying a centromeric plasmid encoding ADE2 and LST8 (pZL1255) were streaked 
on YPD medium.  
(B) SAC7 complements a leb1 mutation. leb1 mutant cells (lst8Δ ade2Δ leb1) carrying 
pRS412-LST8 and either pRS416 empty vector (Vector) or pRS416-SAC7 (SAC7, 
pZL2422) were grown on YNBcasD medium supplemented with adenine.  
(C) FAR11 complements a leb2 mutation. leb2 (lst8Δ ade2Δ leb2) mutant cells carrying 
pRS412-LST8 and either pRS416 empty vector (Vector) or pRS416-FAR11 (FAR11, 
pZL2550) were grown on YNBcasD medium supplemented with adenine. 
(D) Diagram of colony sectoring assay 
(E) Scheme for recovering and identifying the location of a transposon insertion within 
the yeast genome. Sequence obtained can be compared to the Saccharomyces Genome 
Database to identify location of insertion. Adapted from the TRIPLES database 
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2.4.2. sac7Δ and far11Δ mutants are sensitive to rapamycin 
Whether the essential function of Lst8 is linked to TORC1, TORC2, or both has 
yet to be determined. I tested the ability of sac7Δ and far11Δ mutations to suppress 
TORC1 inactivation by rapamycin treatment and TORC2-deficiency due to a 
temperature-sensitive tor2-21 mutation. An fpr1Δ mutation enables cells to grow in the 
presence of rapamycin, however, far11Δ lst8Δ, far11Δ (far11Δ lst8Δ pRS412-LST8), sac7Δ 
lst8Δ and sac7Δ (sac7Δ lst8Δ pRS412-LST8) cells were unable to grow on YPD medium 
supplemented with 200 nM rapamycin (Fig. 2A), demonstrating that these two lst8Δ 
bypass mutations do not suppress a severe or complete loss of TORC1 activity. 
Consistently, sac7Δ and far11Δ mutations failed to restore cell growth to tor1Δ tor2-21 
double mutants grown at 37 °C, which have defects in the function of both TORC1 and 
TORC2 (Appendix Fig. A1 and (102)). In contrast, sac7Δ and far11Δ mutations restored 
cell growth to a tor2-21 mutant grown at 37 °C, which causes a specific defect in only 
TORC2 (Fig. 3C and 4C), consistent with previous findings that sac7Δ suppresses a tor2-
21 mutation (102). These data suggest that the essential function of Lst8 may be linked 
to TORC2, but not TORC1.  
It is conceivable that lst8Δ may result in a partial loss of TORC1 activity, which is 
not sufficient to support cell growth but is not severe enough to prevent sac7Δ and 
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far11Δ mutations from restoring partial cell growth to lst8Δ mutant cells. To test this 
possibility, I tested the sensitivity of wild type, fpr1Δ, sac7Δ, and far11Δ mutant cells to 
lower concentrations of rapamycin (Appendix Fig. A2). It has been reported that sac7Δ 
and far11Δ mutant strains in the BY4741 background are hypersensitive to treatment 
with 10 nM rapamycin (128). In the presence of <10 nM rapamycin, a far11Δ mutant in 
the BY4741 background has been reported to grow better than wild-type cells (60). I 
analyzed cell growth in the presence of 2-20 nM rapamycin and found that sac7Δ 
resulted in hypersensitivity to rapamycin treatment. A far11Δ mutant, in contrast, grew 
slightly better than wild-type cells when treated with 3 and 5 nM rapamycin. In the 
presence of 7-20 nM rapamycin, however, far11Δ cells no longer grew better than wild-
type cells. In my strain background, treatment of wild-type cells with 10 nM rapamycin 
likely reduces TORC1 activity to just below the threshold that supports cell growth. My 
observations that sac7Δ and far11Δ bypass lst8Δ but not treatment with 10 nM 
rapamycin strongly suggest that the essential function of lst8 is not linked to TORC1.  
To further corroborate my hypothesis that Lst8 is not essential for TORC1 
activity, the effect of lst8Δ on the expression of genes encoding ribosomal proteins (RP), 
which is positively regulated by TORC1, was examined. Utilizing sac7Δ to obtain a 
viable lst8Δ mutant, the expression of two RP genes, RPL3 and RPS6A, encoding the L3 
protein of the large (60S) ribosomal subunit and the S6 protein of the small (40S) 
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ribosomal subunit, respectively, was compared in LST8 sac7Δ versus lst8Δ sac7Δ mutant 
cells by Northern blot analysis. As expected, TORC1 inactivation due to rapamycin 
treatment inhibited expression of both RPL3 and RPS6A (Fig. 2B). In contrast, lst8Δ only 
mildly reduced the expression of RPL3 and RPS6A, suggesting that lst8Δ does not lead 
to severe loss of TORC1 activity.   
2.4.3. lst8Δ causes mislocalization of Bit61 and Avo3, but not Kog1 
Recent research has demonstrated that the TORC1 components are located on 
intracellular membranes with a concentration on the vacuolar membrane while TORC2 
components appear as punctate spots at the plasma membrane (3, 10, 12, 113, 121). It 
has been proposed that plasma membrane localization of TORC2 is essential for cell 
viability (10). Isolation of lst8Δ mutant suppressors allowed me to examine the role of 
Lst8 in the cellular localization of TOR complex components. GFP fluorescence was 
analyzed in sac7Δ far11Δ double and sac7Δ far11Δ lst8Δ triple mutants expressing GFP-
tagged TORC1 component Kog1 and TORC2 components Bit61 and Avo3. As 
previously reported, Bit61 and Avo3 localized to the plasma membrane as punctate 
spots in wild-type LST8 cells (Fig. 2C) (10). An lst8Δ mutation, however, largely 
abolished punctate plasma membrane localization of Bit61 and Avo3. In contrast, lst8Δ 
did not affect localization of Kog1 to the vacuolar membrane (Figure 2C). These 
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findings are consistent with my hypothesis that the essential function of Lst8 is linked 
to TORC2, but not TORC1, and further suggest that Lst8 is required for proper cellular 
localization of TORC2.   
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Figure 2.  TORC1 function is not grossly affected in an lst8Δ mutant.  
C
lst8Δ
LS
T
8
GFP
DIC
DIC
GFP
Kog1-GFPAvo3-GFPBit61-GFPNo GFP
YPD
fpr1Δ
WT
sac7Δ
lst8Δ
sac7Δ
far11Δ
far11Δ
lst8Δ
YPD +
Rapamycin
RPL3
RPS6A
ACT1
sa
c7
Δ
sa
c7
Δ ls
t8
Δ
+V
eh
+ 
Ra
pa
sac7Δ
A
B
  
40 
 
(A) sac7Δ and far11Δ mutations do not confer resistance to rapamycin. Wild type 
(ZLY423) and isogenic mutant cells as indicated (far11Δ lst8Δ TPY115; far11Δ, TPY114; 
fpr1Δ, TPY122; sac7Δ lst8Δ, ZLY2405; sac7Δ, ZLY2404) were grown on YPD medium 
with or without 200 nM rapamycin. The lack of a pRS412-LST8 plasmid results in the 
far11Δ lst8Δ and sac7Δ lst8Δ double mutant cells having a red phenotype.  
(B) lst8Δ has little effect on the expression of RPL3 and RPS6A. Expression of RPL3, 
RPS6A and ACT1 in sac7Δ mutant cells (ZLY2404) treated with drug vehicle (+Veh) or 
200 nM rapamycin (+Rapa), sac7Δ single (ZLY2404) and sac7Δ lst8Δ double (ZLY2845) 
mutant cells were analyzed by Northern blotting as described in Materials and 
Methods. 
 (C) lst8Δ causes mislocalization of Bit61 and Avo3, but not Kog1. Wild-type LST8 (LST8 
sac7Δ far11Δ) and lst8Δ mutant (lst8Δ sac7Δ far11Δ) cells expressing no GFP-tagged 
proteins (TPY1264, TPY1266), Bit61-GFP (TPY358, TPY366), Avo3-GFP (TPY369, 
TPY407), or Kog1-GFP (TPY371, TPY413) were grown in SD medium and observed by 
bright field (DIC) and GFP fluorescence microscopy. GFP fluorescence images were 
captured and processed using the same parameters. Arrows indicate punctate plasma 
membrane localization of Bit61 and Avo3. Background signals in cells expressing no 
GFP-tagged proteins, especially in the lst8Δ mutant strain, are due to autofluorescence 
caused by an ade2 mutation.  
  
41 
 
2.4.4. Mutations of the Far3-7-8-9-10-11 Complex bypass lst8Δ and tor2-21 
mutations 
Far11 has been shown to be involved in cell cycle arrest in response to mating 
pheromone in a multi-protein complex with Far3, Far7, Far8, Far9, and Far10 (59, 68). 
Interactions among these six Far proteins are based mostly on yeast two-hybrid assays 
(68, 73); however, Far3 has been reported to interact with Far11 by 
coimmunoprecipitation. I generated strains coexpressing HA-tagged Far11 and myc-
tagged Far7, Far8, Far9, Far10, and Far11 under the control of their respective 
endogenous promoters to test whether Far11 interacts with Far7, Far8, Far9, Far10 or 
itself by coimmunoprecipitation. FAR11-HA was found to be functional by its ability to 
complement a far11Δ mutation using the colony-sectoring assay described for Figure 1C 
(Appendix Fig. A3). myc-tagged Far proteins are functional as described previously 
(68). Far11-HA in cell lysates prepared for coimmunoprecipitation exists as two bands 
on Western blots (Fig. 3A). The faster mobility form of Far11-HA is likely to be a 
proteolytically truncated form of Far11 since Far11-HA exists as a single band on 
Western blots when the total cellular proteins were prepared by disrupting cells in the 
presence of 1.85N NaOH-7.5% β-mercaptoethanol and followed by precipitation with 
trichloroacetic acid (Appendix Fig. A4). myc-tagged proteins were precipitated from 
cell lysates using anti-myc antibody. Figure 3A shows that Far11-HA 
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coimmunoprecipitates with myc-tagged Far7, Far8, Far9, Far10, but not Far11, 
demonstrating that Far11 interacts with other Far proteins in vivo. 
Since Far11 is part of a multi-protein complex, it is possible that the entire 
complex is involved in TORC2 signaling. I examined whether mutations of the Far 
complex bypass lst8Δ and tor2-21 as well. lst8Δ farΔ double mutants each carrying a 
centromeric plasmid encoding LST8 and URA3 ([CEN URA LST8]) were grown on SD 
medium without or with 5-fluoroorotic acid (5-FOA), which selects for cells that have 
lost the URA3 plasmid. Based on their relative growth in the presence of 5-FOA, 
mutations in FAR3, FAR7, FAR8, FAR9, FAR10, and FAR11 bypass lst8Δ to varying 
degrees: far11> far8/9> far3/7> far10 (Fig. 3B). farΔ mutations were subsequently found to 
suppress a tor2-21 mutation at 37 °C (Fig. 3C). The tor2-21 suppression phenotypes of 
far3, far7, far8, far9, far10, and far11 mutations largely mirror that of their respective lst8Δ 
bypass (Fig. 3B and C), indicating that the function of Lst8 is tightly linked to TORC2.  
Far9 and Far10 are homologous proteins with 31% sequence identity and 47% 
sequence similarity, yet they have different lst8Δ and tor2-21 suppression phenotypes. I 
generated a tor2-21 far9Δ far10Δ triple mutant and found that its growth was only 
marginally better than the tor2-21 far9Δ double mutant (Appendix Fig. A5), indicating 
that of the two, Far9 plays the primary role in TORC2 signaling.  
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It is unclear whether an lst8Δ or tor2-21 mutation leads to complete loss of 
TORC2 activity. Deletion of TOR2, encoding the only TOR kinase in TORC2, abolishes 
TORC2 activity. To test whether far11Δ bypasses tor2Δ, spores of tetrads from 
FAR11/far11 TOR2/tor2Δ::kanMX4 diploid cells were assessed for viability. All tetrads 
produced at most two viable spores, none of which were geneticin-resistant (kanXM4 
confers geneticin resistance) (Appendix Fig. A6). Since FAR11 and TOR2 are not located 
on the same chromosome, 25% of spores should have the genotype tor2Δ::kanMX4 
far11Δ. Failure to obtain viable geneticin-resistant spores indicates that far11Δ is unable 
to bypass tor2Δ. Similarly, I found that far11Δ failed to bypass avo1Δ or avo3Δ (Appendix 
Fig. A6). Since far11Δ is able to suppress lst8Δ and tor2-21 mutations, it is likely that 
lst8Δ and tor2-21 mutations do not completely abolish TORC2 activity and that far11Δ 
can restore growth to cells with a severe loss, but not a total loss of TORC2 activity.    
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Figure 3.  Mutations in FAR3, FAR7, FAR8, FAR9, FAR10, and FAR11 bypass lst8Δ and 
tor2-21 mutant phenotypes.  
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 (A) Far11-HA interacts with myc-tagged Far7, Far8, Far9, and Far10. Cell lysates of 
strains TPY978 (Far7-myc), TPY981 (Far8-myc), TPY1001 (Far9-myc), TPY1002 (Far10-
myc), and TPY1003 (Far11-myc) coexpressing Far11-HA (pZL2762) were subjected to 
immunoprecipitation with anti-myc antibody. HA- and myc-tagged proteins were 
detected by Western blotting. * denotes a likely truncation product of Far11-HA.  
(B) Mutations in FAR3, FAR7, FAR8, FAR9, FAR10, and FAR11 bypass lst8Δ. Serial 
dilutions of wild-type (RBY231) and isogenic mutant cells (lst8Δ, RBY223; lst8Δ far3Δ, 
MOY142; lst8Δ far7Δ, MOY145; lst8Δ far8Δ, MOY146; lst8Δ far9Δ, MOY169; lst8Δ far10Δ, 
MOY149; lst8Δ far11Δ, MOY150 ) carrying a centromeric plasmid encoding URA3 and LST8 
(pZL339) as indicated were grown on SD medium without or with 5-FOA.  
(C) Mutations in FAR3, FAR7, FAR8, FAR9, FAR10, and FAR11 suppress tor2-21 at 37 °C. 
Serial dilutions of indicated cells (WT, SH100; tor2-21, SH121; tor2-21 far3Δ, TPY157; tor2-21 
far7Δ, TPY147; tor2-21 far8Δ, TPY213; tor2-21 far9Δ, TPY207; tor2-21 far10Δ, TPY151; tor2-21 
far11Δ, TPY116 ) were grown on YPD medium at 30 °C and 37 °C for 3-4 days. 
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2.4.5. sac7Δ and far11Δ additively suppress tor2-21 
TORC2 is involved in the organization of the actin cytoskeleton. A tor2-21 
mutant shows depolarization of the actin cytoskeleton and several tor2-21 suppressors 
can restore actin polarization to tor2-21 mutant cells (102). I compared actin structures in 
wild-type, tor2-21, tor2-21 sac7Δ, and tor2-21 far11Δ mutant cells to establish whether 
actin polarization defects caused by a tor2-21 mutation could be restored by a 
far11Δ mutation. As expected, a sac7Δ mutation restored polarization of the actin 
cytoskeleton in tor2-21 mutant cells grown at 37 °C (Fig. 4A). Similarly, a far11Δ 
mutation restored polarization of actin structures in tor2-21 mutant cells grown at 37 °C 
(Fig. 4B). A recent genome-wide study of genetic interactions in yeast showed that 
far11Δ restored actin polarization to tsc11-1 (avo3-1) mutant cells (7). Together, these 
data establish that Far11 negatively regulates TORC2-mediated polarization of the actin 
cytoskeleton. 
Similar phenotypes of far11Δ and sac7Δ mutations prompted me to determine 
whether they act through the same molecular mechanism. Accordingly, I compared the 
growth of a tor2-21 sac7Δ far11Δ triple mutant to wild-type, tor2-21, tor2-21 sac7Δ, and 
tor2-21 far11Δ mutants at 30 °C versus 37 °C. Figure 4C shows that while all strains grew 
equally well at 30 °C, the tor2-21 sac7Δ far11Δ mutant grew better than either the tor2-21 
  
47 
 
far11Δ or the tor2-21 sac7Δ mutant at 37 °C, indicating that far11Δ and sac7Δ have 
additive effects in suppressing tor2-21. To examine whether sac7Δ and far11Δ have an 
additive effect in suppressing an actin depolarization defect in tor2-21 mutant cells, I 
determined the percentage of cells with polarized actin cytoskeleton in wild-type and 
isogenic tor2-21, tor2-21 sac7Δ, tor2-21 far11Δ, tor2-21 sac7Δ far11Δ mutant cells. Table 1 
shows that the effect of sac7Δ and far11Δ on the restoration of actin structure 
polarization is additive. Sac7 and Rom2 have opposing roles in mediating TORC2 
function and it has been proposed that Tor2 activates Rho1 via Rom2 (102). Therefore, 
to determine whether tor2-21 suppression by far11Δ is Rom2-dependent, I introduced a 
rom2Δ mutation into the tor2-21 far11Δ mutant. Figure 4D shows that a rom2Δ mutation 
greatly reduced the tor2-21 suppression phenotype of a far11Δ mutation at 37 °C but did 
not abolish it, suggesting that far11Δ suppression of TORC2-deficiency is not entirely 
dependent on the Rom2-mediated Rho1/2 GTPase switch. 
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Figure 4.  sac7Δ and far11Δ additively suppress tor2-21.  
(A-B) Mutations in SAC7 and FAR11 restore polarization of the actin cytoskeleton to 
tor2-21 mutant cells grown at 37 °C. Actin structures in indicated cells (WT, SH100; tor2-
21, SH121; tor2-21 sac7Δ, TPY110; tor2-21 far11Δ TPY116) were detected by staining with 
rhodamine phalloidin as described in Materials and Methods.  
(C) sac7Δ and far11Δ have an additive effect in suppressing tor2-21. Serial dilutions of 
indicated cells (WT, SH100; tor2-21, SH121; tor2-21 sac7Δ, TPY110; tor2-21 far11Δ TPY311; 
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tor2-21 sac7Δ far11Δ, TPY301) were grown on YPD medium at 30 °C and 37 °C for 2-3 
days.  
(D) far11Δ suppression of tor2-21 is partially dependent on ROM2. Serial dilutions of 
indicated cells (WT, SH100; tor2-21, SH121; tor2-21 far11Δ TPY311; tor2-211 far11Δ rom2Δ, 
TPY680) were grown on YPD medium at 30 °C and 37 °C.  
 
 
 
Table 1.  Quantitative analysis of polarization of the actin cytoskeleton. 
Strain # cells imaged # polarized cells % polarized cells 
Wild-type 474 357 75.3% 
tor2-21 424 89 21.0% 
tor2-21 sac7Δ 504 267 53.0% 
tor2-21 far11Δ 461 240 52.1% 
tor2-21 sac7Δ far11Δ 451 318 70.5% 
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2.4.6. Far11 interacts with Tpd3 and Pph21, components of PP2A 
The data so far raise the question: How does the Far3-7-8-9-10-11 complex 
mediate TORC2 signaling? The human ortholog of yeast Far11 exists in the human 
STRIPAK complex, which also contains components of PP2A (48). The Far11 ortholog in 
Drosophila has also been reported to interact with PP2A in the dSTRIPAK complex (96). 
Therefore, I tested whether Far11 in yeast also exists in a complex with PP2A. In yeast, 
the heterotrimeric PP2A phosphatase consists of the regulatory A subunit Tpd3, the 
regulatory B subunit Cdc55 or B’ subunit Rts1, and one of the two homologous and 
functionally redundant catalytic C subunits Pph21 or Pph22 (34). Among approximately 
75 proteins that genetically or biochemically interact with Far11 in various genome-
wide gene/protein interaction studies (Saccharomyces Genome Database), Tpd3 has been 
found to interact with Far11 by yeast two-hybrid analysis (119). The significance of this 
interaction remains unknown.  
To establish the interaction between Far11 and PP2A in yeast, lysates from cells 
coexpressing 3x HA-tagged Far11 and 3x myc-tagged Tpd3 or Pph21 were subjected to 
immunoprecipitation using anti-myc antibody. TPD3-myc and PPH21-myc constructs 
were found to be functional by their ability to rescue growth defects of tpd3Δ and 
pph21/22Δ mutants respectively (Appendix Fig. A7). No Far11-HA was detected in the 
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IP pellet from cells expressing Far11-HA alone. In contrast, Far11-HA was recovered in 
the IP pellet from cells coexpressing Tpd3-myc, and to a lesser extent, from cells 
coexpressing Pph21-myc (Fig. 5A) likely because C-terminal tagging of Pph21 perturbs 
methylation at its C-terminus required for PP2A complex stability (122). These findings 
establish that Far11 interacts with PP2A phosphatase. 
2.4.7. Defects in PP2A-Rts1 bypass lst8Δ and tor2-21 mutations 
To investigate whether PP2A is involved in TORC2 signaling, I examined 
whether mutations in PP2A components bypass lst8Δ. I analyzed the growth of an lst8Δ 
tpd3Δ double mutant, an lst8Δ rts1Δ double mutant, an lst8Δ cdc55Δ double mutant, and 
an lst8Δ pph21Δ pph22Δ triple mutant each carrying a centromeric plasmid encoding 
URA3 and LST8 on SD medium without or with 5-FOA. tpd3Δ, rts1Δ, and pph21/22Δ 
mutations, but not a cdc55Δ mutation, were able to bypass lst8Δ (Fig. 5B and C), 
indicated by their ability or inability to grow in the presence of 5-FOA, suggesting that 
reduced activity in the PP2A-Rts1 subcomplex results in lst8Δ bypass. I then tested 
whether rts1Δ and tpd3Δ mutations suppress tor2-21. Figure 5D shows that rts1Δ 
suppresses a tor2-21 mutation by restoring cell growth at 37 °C. A tpd3Δ mutation led to 
temperature-sensitive growth defects in the TOR2 wild-type strain used in my study; 
therefore, I could not assay tor2-21 suppression by tpd3Δ. These findings indicate that 
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mutations in genes encoding components of the PP2A-Rts1 subcomplex suppress 
TORC2-deficiency. 
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Figure 5. Mutations in TPD3, RTS1 and PPH21/22 suppress TORC2 deficiency.  
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(A) Far11-HA interacts with Tpd3-myc and Pph21-myc. Cell lysates of far11Δ mutant 
cells (BY4741 far11) expressing Far11-HA only (pZL2762), tpd3Δ far11Δ double mutant 
cells (TPY633) coexpressing Far11-HA and Tpd3-myc (pTP242), and pph21/22Δ far11Δ 
triple mutant cells coexpressing Far11-HA and Pph21-myc (pTP244) were subject to 
immunoprecipitation with anti-myc antibody. IgG HC indicates the heavy chain of the 
anti-myc antibody used for Co-IP. * denotes a likely truncation product of Far11.  
(B) Mutations in TPD3 and RTS1 bypass lst8Δ. Serial dilutions of wild-type (WT, 
RBY231), lst8Δ (RBY223), lst8Δ tpd3Δ (TPY625), lst8Δ rts1Δ (TPY648), and lst8Δ cdc55Δ 
mutant (TPY732) cells carrying a centromeric plasmid encoding LST8 ([URA3 LST8], 
pZL339) were grown on SD medium without or with 5-FOA.  
(C) A pph21/22Δ double mutation bypasses lst8Δ. Serial dilutions of wild-type cells (WT, 
BY4741) carrying an empty vector pRS416, lst8Δ single (BY4741 lst8), pph21/22Δ double 
(BY4741 pph21/22) and lst8Δ pph21/22Δ triple (TPY622) mutant cells carrying a plasmid 
encoding LST8 (pZL339) were tested for growth as described for panel B.  
(D) An rts1Δ mutation suppresses tor2-21 at 37 °C. Serial dilutions of wild-type (SH100), 
tor2-21 (SH121), rts1Δ (TPY665), and tor2-21 rts1Δ (TPY601) cells were grown on YPD 
medium at 30 °C and 37 °C.  
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2.4.8. far11Δ and rts1Δ restore phosphorylation of Slm1 in a tor2-21 mutant 
One known function of TORC2 is its role in the organization of the actin 
cytoskeleton possibly by phosphorylating Slm1, Slm2, and Ypk2. The data above show 
that far11Δ, sac7Δ and rts1Δ mutations suppress a tor2-21 mutation and that Far11 
interacts with PP2A. Therefore, I tested the possibility that Far11 may mediate 
dephosphorylation of Slm1, Slm2, and/or Ypk2 via PP2A by evaluating the 
phosphorylation states of Slm1, Slm2, and Ypk2 in wild-type, tor2-21, tor2-21 far11Δ, 
tor2-21 sac7Δ, and tor2-21 rts1Δ  mutant cells each expressing Slm1-HA, Slm2-HA, or 
Ypk2-HA from their respective endogenous promoters. Ypk2 and Slm2’s 
phosphorylation states did not differ between the wild-type and the tor2-21 mutant 
grown at 37 °C (Appendix Fig. A8). Therefore, Ypk2 and Slm2 were not studied further. 
Consistent with previous reports on the phosphorylation state of GFP-tagged Slm1 (5), 
Figure 6A shows that Slm1-HA is phosphorylated: lambda protein phosphatase (λ 
PPase) treatment resulted in increased levels of the faster mobility forms of Slm1-HA 
with concomitant reduced levels of the slower mobility forms of Slm1-HA; phosphatase 
inhibitors largely abolished the effect of λ PPase treatment. As reported previously, 
Figure 6B shows that Slm1 is dephosphorylated in tor2-21 mutant cells grown at 37 °C 
(5). Remarkably, far11Δ, but not sac7Δ, restored Slm1-HA phosphorylation to tor2-21 
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mutant cells grown at 37 °C (Fig. 6B), implicating Far11 in Slm1 dephosphorylation and 
suggesting that suppression of TORC2-deficiency by a sac7Δ mutation takes place 
downstream of Slm1. Furthermore, Slm1-HA was phosphorylated in tor2-21 rts1Δ 
mutant cells grown at 37 °C (Fig. 6C). These data suggest that Far11-PP2A-Rts1 may 
antagonize TORC2 activity and decrease the levels of the phosphorylated form of the 
TORC2 substrate Slm1. 
  
57 
 
 
 
 
 
 
 
 
 
Figure 6. Mutations in RTS1 and FAR11, but not SAC7, restore SLM1 phosphorylation 
in tor2-21 mutant cells.  
(A) Slm1-HA is phosphorylated. Cell lysates from wild-type cells (SH100) expressing 
Slm1-HA (pTP311) were prepared and treated with lambda protein phosphatase 
(λPPase) with or without phosphatase inhibitors as described in Materials and 
Methods. Slm1-HA was detected by Western blotting. * indicates phosphorylated Slm1. 
(B) A mutation in FAR11, but not in SAC7, restores Slm1 phosphorylation in tor2-21 
mutant cells grown at 37 °C. Indicated cells (WT, SH100; tor2-21, SH121; tor2-21 far11Δ, 
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TPY116; tor2-21 sac7Δ, TPY110) expressing Slm1-HA were grown in YNBcasD medium 
at 30 °C to mid-log phase and switched to 37 °C for 3h before cellular proteins were 
processed for Western blotting.  
(C) An rts1Δ mutation restores Slm1 phosphorylation in tor2-21 mutant cells grown at 
37 °C. Indicated cells (WT, SH100; tor2-21, SH121; rts1Δ, TPY665; tor2-21 rts1Δ, TPY601) 
expressing Slm1-HA were analyzed for Slm1-HA phosphorylation as described for 
panel B.  
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2.4.9. Effects of sac7Δ and far11Δ mutations on Tor2 kinase activity 
Sac7 has been proposed to function downstream of TORC2. The genetic data 
suggest that Far11-PP2A-Rts1 antagonizes TORC2 signaling. It is possible that Far11-
PP2A-Rts1 may function downstream of TORC2 and promote dephosphorylation of 
TORC2 substrates. It is also likely that Far11-PP2A-Rts1 may function upstream of 
TORC2 and negatively impact TORC2 activity. To differentiate between these two 
possibilities, the activity of immunopurified Tor2 with a N-terminal 3xHA tag from 
wild-type and isogenic far11Δ mutant cells was determined in an in vitro kinase assay 
using Slm1 as a substrate. Slm1 has been reported to be a TORC2 substrate in in vitro 
kinase assays (5, 37). For the assays, recombinant 6xHis-tagged Slm1was added to 
kinase reactions with immunopurified HA-Tor2 and [γ-32P]-ATP. Figure 7 shows that 
far11Δ has no significant effect on kinase activity of immunopurified HA-Tor2, 
suggesting that Far11 functions at a site downstream of TORC2.  
Similarly, I performed an in vitro kinase assay using HA-Tor2 from sac7Δ mutant 
cells. Surprisingly, sac7Δ slightly increases kinase activity of immunopurified HA-Tor2 
(Fig. 7). Mutations in SAC7 have been proposed to activate Rho1, which in turn 
activates Pkc1 and the cell wall integrity MAP kinase cascade. Increased activity of Tor2 
in sac7Δ mutant cells suggests positive feedback regulation in TORC2 signaling. 
  
60 
 
Differential effects of sac7Δ and far11Δ mutations on Tor2 kinase activity further support 
the notion that Sac7 and Far11 mediate TORC2 signaling through different mechanisms. 
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Figure 7. In vitro phosphorylation of Slm1 by immunopurified HA-Tor2.  
(A) Wild-type (SW70) and isogenic sac7Δ (TPY1246) and far11Δ (TPY1249) cells 
expressing N-terminal 3xHA-tagged Tor2 from the TOR2 genomic locus were grow in 
YPD medium. Slm1-His6 phosphorylation assays by HA-Tor2 were conducted as 
described in Materials and Methods. Phospho-Slm1-His6 was detected by 
autoradiography. Total Slm1-His6 and HA-Tor2 in the assays were detected by 
Coomassie Blue staining and immunoblotting, respectively. The result of a mock kinase 
assay using cell lysates from wild-type cells expressing native, nontagged Tor2 (TB50a) 
was included in lane 1.  
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(B) The amount of phospho-Slm1-His6 was normalized to that of HA-Tor2 and 
graphed. Kinase assays were performed with HA-Tor2 from two independent cell 
lysates and the error bar indicates the standard deviation. 
  
63 
 
2. 5. Discussion     
Lst8 is an essential protein that exists in both TOR kinase complexes. I found that 
mutations in genes encoding the PP2A-Rts1 subcomplex and the Far3-7-8-9-10-11 
complex bypass lst8Δ and TORC2-deficiency. Analysis of these mutants led me to 
propose that the essential function of Lst8 is linked to TORC2. The Far3-7-8-9-10-11 
complex components are partially conserved in Drosophila and mammals, and have 
been reported to interact with PP2A phosphatase in the STRIPAK complex. I showed 
that the Far3-7-8-9-10-11 complex and PP2A negatively regulate TORC2 signaling 
possibly by mediating dephosphorylation of the TORC2 substrate Slm1, depicted by the 
proposed model in Figure 8. My results not only demonstrate that the essential function 
of Lst8 is only linked to TORC2, but more importantly, reveal a novel link between the 
two major signaling protein complexes PP2A and TORC2. 
2.5.1. The essential function of Lst8 is linked to TORC2, but not TORC1 
Yeast Lst8 has been reported to be important for TORC2 complex integrity in vivo 
and Tor2 kinase activity in vitro (126). Underlying its importance in TORC2 activity, the 
presence of Lst8 in TORC2 has been reported in multiple organisms including yeast, 
slime mold, worms, flies, and mammals (28). Consistently, my data demonstrate that 
the essential function of Lst8 is linked to TORC2. Delocalization of Bit61 and Avo3 from 
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punctate structures at the plasma membrane in lst8Δ mutant cells likely results from 
compromised TORC2 integrity in the absence of Lst8, indicating that Lst8 is also 
required for proper localization of the TORC2 complex.  
Lst8 interacts with the kinase domain of Tor2 in yeast TORC2 (126). Since far11Δ 
bypasses lst8Δ and tor2-21, but not tor2Δ, avo1Δ, and avo3Δ, my data suggest that neither 
lst8Δ nor the temperature-sensitive tor2-21 mutation leads to total loss of TORC2 
activity. This possibility helps explain my observation that far11Δ and rts1Δ can restore 
Slm1 phosphorylation to tor2-21 mutant cells at the restrictive temperature: If tor2-21 led 
to total loss of TORC2 activity and consequent loss of Slm1 phosphorylation, PP2A 
inactivation could not restore Slm1 phosphorylation unless other protein kinases also 
phosphorylate Slm1. In this scenario, TORC2 would share a redundant function with 
the other putative kinase in phosphorylating Slm1 and may have another essential 
function separate from its kinase activity, for example, by maintaining interactions with 
other proteins to conduct downstream signaling. 
Three TORC2 substrates in yeast are Slm1, Slm2, and Ypk2. A constitutively 
active Ypk2 mutant can restore growth to tor2Δ mutant cells, leading to the proposal 
that the essential function of TORC2 is mainly linked to Ypk2 phosphorylation (28, 66). 
There is strong evidence that functionally redundant Slm1 and Slm2 are essential 
  
65 
 
substrates of TORC2. Firstly, Slm1 has been reported to interact with TORC2 and to be 
phosphorylated by TORC2 (5, 37). Secondly, TORC2-dependent phosphorylation of 
Slm1 seems to correlate with its plasma membrane association (5). Slm1 contains a PH 
domain that binds to multiply phosphorylated phosphoinositides and is required for 
Slm1’s plasma membrane localization (37), and putative loss of plasma membrane 
association of Slm1/2 leads to cell death. Thirdly, a sac7Δ mutation suppresses both a 
tor2-21 mutation and a slm1Δ slm2Δ double mutation, and the actin cytoskeleton is 
depolarized in both slm1/2 and tor2-21 mutant cells. Although I could not test whether 
phosphorylation of Slm2 and Ypk2 in a tor2-21 mutant is restored by far11 and rts1 
mutations, it is likely that due to mutations in Far11-PP2A, increased phosphorylation 
of Slm1, Slm2, and/or Ypk2 leads to cell viability in TORC2-deficient cells.  
The presence of Lst8 in TORC1 is conserved from yeast to mammals. In yeast, 
Lst8 localizes not only to the TORC1 compartment at the vacuolar membrane, but also 
to the TORC2 compartment as punctate structures at the plasma membrane (10). Similar 
to its interaction with Tor2 in TORC2, in yeast and humans, Lst8 interacts with the Tor1 
kinase domain in the TORC1 complex (1, 70). Therefore, the observation that Lst8 is not 
required for TORC1-dependent expression of genes encoding ribosomal proteins and 
Kog1 localization at the vacuolar membrane is surprising, raising the question: Is Lst8 
required for TORC1 activity at all? Missense mutations in LST8 increase the expression 
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of a subset of TORC1-target genes (25, 45). Therefore, Lst8 is likely to be required for 
optimal TORC1 activity, but an lst8Δ mutation may not reduce TORC1 activity severely 
enough to lead to cell death. In mammals, the role of Lst8 in mTORC1 is unclear. mLst8 
knockdown in human immortalized cell lines suggested that mLst8 is important for 
mTORC1 activity (70). Later in mice, mLst8 was found to be important for mTORC2, 
but not mTORC1 function during mouse development (50). The discrepancy could be 
attributed to the differences between a developing mouse embryo and an immortalized 
human cell line. However, the conclusions concerning the role of Lst8 in both yeast and 
mouse are similar: the essential function of Lst8 is linked to TORC2 but not TORC1.     
2.5.2. Far3-7-8-9-10-11-PP2A as a negative regulator of TORC2 signaling 
One of the important findings presented here is a negative regulatory role of the 
Far3-7-8-9-10-11 complex and PP2A in TORC2 signaling. Considering the extensive 
studies on PP2A and TORC2, it is surprising that, to my knowledge, this study may 
represent the first to present a direct genetic interaction between TORC2 and PP2A. 
More importantly, my data mirror a recent study in Drosophila demonstrating that the 
Drosophila Far complex works in concert with PP2A in the regulation of a different 
kinase pathway, the Hippo signaling pathway (96). Thus, PP2A regulation by the Far 
protein complex appears to be evolutionarily conserved. In a proteomics study, the 
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yeast Far11 orthologs, Fam40A and Fam40B (STRIP1/2) were isolated in the STRIPAK 
complex, which also contains components of PP2A. Interestingly, far11Δ leads to the 
strongest suppression of TORC2-deficiency, and among the six Far proteins, Far11 is the 
most conserved. Far9 and Far10 are homologous proteins and their Drosophila and 
mammalian orthologs show limited sequence homology, mostly in an FHA domain, 
which is known to interact with phosphothreonine epitopes on target proteins (33). Far8 
shows very limited sequence homology to striatin (48). The question remains: How 
does the Far3-7-8-9-10-11 complex affect PP2A activity? Interaction between Far11 and 
Tpd3, the scaffolding subunit of PP2A suggests that the Far complex may directly 
regulate PP2A by either targeting the TORC2 substrate Slm1 and/or mediating PP2A 
activity. Unlike slow cell growth phenotypes due to a tpd3Δ single or a pph21/22Δ 
double mutation, mutations in FAR3, FAR7, FAR8, FAR9, FAR10,and FAR11 have little 
or no growth defects, suggesting that the Far complex is not integral to PP2A activity. In 
both the Drosophila study and this one, mutations in PP2A and/or Far components of the 
STRIPAK complex lead to increased phosphorylation of target proteins. Thus, it is 
possible that the Far complex might target certain substrates to PP2A.  
This study demonstrates that Far11-PP2A-Rts1 modulates Slm1 phosphorylation 
by counteracting the kinase activity of TORC2, providing a molecular mechanism to 
explain how mutations in FAR11 and genes encoding PP2A-Rts1 components might 
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suppress TORC2-deficiency. The calcineurin phosphatase also mediates Slm1 
dephosphorylation and counteracts TORC2 signaling (19, 30, 87). It was further shown 
that mutations in cnb1, encoding the regulatory subunit of calcineurin, suppress an avo3 
temperature-sensitive mutation (4). It remains to be determined whether a cnb1 
mutation restores phosphorylation of Slm1 to TORC2-deficient cells. Ypk2 is another 
essential effector of TORC2. Mutations in calcineurin could potentially restore 
phosphorylation of Ypk2 in avo3 mutant cells, thereby suppressing the avo3 
temperature-sensitive growth phenotype. Furthermore, in a genome-wide study on 
genetic interactions in yeast, mutations in PPG1, encoding a PP2A-like phosphatase, 
also suppress TORC2-deficiency (7). Therefore, it is likely that these phosphatases may 
work together to mediate TORC2 signaling.  
Various genetic screens in fungi have isolated mutations in the Far complex. In 
Neurospora crassa, a mutation in ham-2, the ortholog of yeast FAR11 leads to defects in 
hyphal fusion (127). In Sordaria macrospora, mutations in PRO22, encoding the yeast 
Far11 ortholog, generate a novel type of sterile mutant with a defect in ascogonial 
septum formation (15). In yeast, mutations in FAR9/VPS64 and FAR11/YNL127w result 
in vacuolar sorting defects (16), and mutations in FAR3, FAR7, FAR8, FAR10, and 
FAR11 create long-lived mutants (36). In all of these studies, the underlying 
mechanisms are unknown. In light of my findings, it is possible that these disparate 
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phenotypes are due to the perturbation of PP2A activity and/or TORC2 signaling in 
these mutants.  
  
70 
 
 
 
 
 
 
 
 
 
Figure 8. A model for the regulation of TORC2 signaling by the Far3-7-8-9-10-11 
complex and PP2A-Rts1.  
TORC2 regulates the organization of the actin cytoskeleton via phosphorylation of Slm1 
and Ypk1/2. Far3-7-8-9-10-11-PP2A-Rts1 antagonizes TORC2 signaling by promoting 
Slm1 dephosphorylation. Proteins in bold were analyzed in this study.   
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Table 2.  S. cerevisiae strains used in Chapter 2. 
Strain Genotype Source Application 
ZLY2254 MATa ura3Δ0 leu2Δ0 his3Δ1 met15Δ0 
lst8::kanMX4 ade2Δ::HIS3 [pRS412-
LST8] 
This study  
ZLY3081 
(WT) 
MATα ura3Δ0 leu2Δ0 his3Δ1 met15Δ0 
lst8::kanMX4 ade2Δ::HIS3 [pRS412-
LST8] 
This study Fig. 1
TPY104 
(leb1) 
MATα ura3Δ0 leu2Δ0 his3Δ1 met15Δ0 
lst8::kanMX4 ade2Δ::HIS3 
leb1::Tn3::LEU2 [pRS412-LST8]
This study Fig. 1
TPY103 
(leb2) 
MATα ura3Δ0 leu2Δ0 his3Δ1 met15Δ0 
lst8::kanMX4 ade2Δ::HIS3 
leb2::Tn3::LEU2 [pRS412-LST8]
This study Fig. 1
ZLY423 (WT) MATa ade2-1 ura3 his3-11,15 leu2 
lst8::LEU2 [pRS412-LST8]
This study Fig. 2A
TPY115 
(far11 lst8) 
MATa ade2-1 ura3 his3-11,15 leu2 
lst8::LEU2 far11::kanMX4
This study Fig. 2A
TPY114 
(far11) 
MATa ade2-1 ura3 his3-11,15 leu2 
lst8::LEU2 far11::kanMX4 [pRS412-
LST8] 
This study Fig. 2A
TPY122 
(fpr1) 
MATa ade2-1 ura3 his3-11,15 leu2 
lst8::LEU2 fpr1::kanMX4 [pRS412-
LST8] 
This study Fig. 2A
ZLY2405 
(sac7 lst8) 
MATa ade2-1 ura3 his3-11,15 leu2 
lst8::LEU2 sac7::kanMX4 
This study Fig. 2A
ZLY2404 
(sac7) 
MATa ade2-1 ura3 his3-11,15 leu2 
lst8::LEU2 sac7::kanMX4 [pRS412-
LST8] 
This study Fig. 2A-B
ZLY2845 
(sac7 lst8) 
MATa ade2-1 ura3 his3-11,15 leu2 
lst8::LEU2 sac7::kanMX4 [pRS412]
This study Fig. 2B
TWY680 MATa AVO3-GFP::kanR ura3 trp1 
leu2 his3 ade2 can1-100
(10)  
TWY696 MATa BIT61-GFP::HIS ura3 trp1 leu2 
his3 ade2 can1-100
 
TWY748 MATa KOG1-GFP::HIS ura3 trp1 leu2 
his3 ade2 can1-100
 
TPY1264 
(WT, no GFP) 
MATa sac7::kanMX4 far11::TRP1 
ura3 leu2 his3 ade2 trp1 can1-100 
This study Fig. 2C 
TPY1266 
(lst8, no GFP) 
MATa sac7::HIS3 far11::TRP1 
lst8::LEU2 ura3 leu2 his3 ade2 trp1 
This study Fig. 2C 
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can1-100 
TPY369 
(AVO3-GFP) 
MATa AVO3-GFP::kanR ura3 trp1 
leu2 his3 ade2 can1-100 sac7::HIS3 
far11::TRP1 
This study Fig. 2
TPY407 (lst8 
AVO3-GFP) 
MATa AVO3-GFP::kanR ura3 trp1 
leu2 his3 ade2 can1-100 sac7::HIS3 
far11::TRP1 lst8::LEU2
This study Fig. 2
TPY358 
(BIT61-GFP) 
MATa BIT61-GFP::HIS ura3 trp1 leu2 
his3 ade2 can1-100 sac7::kanMX4 
far11::TRP1 
This study Fig. 2C
TPY366 (lst8 
BIT61-GFP) 
MATa BIT61-GFP::HIS ura3 trp1 leu2 
his3 ade2 can1-100 sac7::kanMX4 
far11::TRP1 lst8::LEU2
This study Fig. 2C
TPY371 
(KOG1-GFP) 
MATa KOG1-GFP::HIS ura3 trp1 leu2 
his3 ade2 can1-100 sac7::kanMX4 
far11::TRP1 
This study Fig. 2C
TPY413 (lst8 
KOG1-GFP) 
MATa KOG1-GFP::HIS ura3 trp1 leu2 
his3 ade2 can1-100 sac7::kanMX4 
far11::TRP1 lst8::LEU2
This study Fig. 2C
SY2227 MATa ade1-1 leu2-2,113 trp1 ura3-52 
bar1 HIS3::pFUS1::HIS3 mfa2-
Δ1::FUS1-lacZ rad16::pGAL1::STE4
(68)  
SY4078 SY2227 FAR7-myc13-KAN 
<pSL2771> 
 
SY4079 SY2227 FAR8-myc13-KAN 
<pSL2771> 
 
SY4080 SY2227 FAR9-myc13-KAN 
<pSL2771> 
 
SY4081 SY2227 FAR10-myc13-KAN 
<pSL2771> 
 
SY4082 SY2227 FAR11-myc13-KAN 
<pSL2771> 
 
TPY978 SY2227 FAR7-myc13-KAN [pRS416-
FAR11-HA] 
This study Fig. 3A
TPY981 SY2227 FAR8-myc13-KAN [pRS416-
FAR11-HA] 
This study Fig. 3A
TPY1001 SY2227 FAR9-myc13-KAN [pRS416-
FAR11-HA] 
This study Fig. 3A
TPY1002 SY2227 FAR10-myc13-KAN 
[pRS416-FAR11-HA]
This study Fig. 3A
TPY1003 SY2227 FAR11-myc13-KAN 
[pRS416-FAR11-HA]
This study Fig. 3A
RBY231 (WT) MATα ura3 leu2 lys2 [pRS416-LST8] This study Fig. 3B, 
  
73 
 
5B 
RBY223 (lst8) MATα ura3 leu2 lys2 lst8::LEU2 
[pRS416-LST8] 
This study Fig. 3B, 
5B 
MOY142 (lst8 
far3) 
MATα ura3 leu2 lys2 lst8::LEU2 
far3::kanMX4 [pRS416-LST8]
This study Fig. 3B
MOY145 (lst8 
far7) 
MATα ura3 leu2 lys2 lst8::LEU2 
far7::kanMX4 [pRS416-LST8]
This study Fig. 3B
MOY146 (lst8 
far8) 
MATα ura3 leu2 lys2 lst8::LEU2 
far8::kanMX4 [pRS416-LST8]
This study Fig. 3B
MOY169 (lst8 
far9) 
MATα ura3 leu2 lys2 lst8::LEU2 
far9::kanMX4 [pRS416-LST8]
This study Fig. 3B
MOY149 (lst8 
far10) 
MATα ura3 leu2 lys2 lst8::LEU2 
far10::kanMX4 [pRS416-LST8]
This study Fig. 3B
MOY150 (lst8 
far11) 
MATα ura3 leu2 lys2 lst8::LEU2 
far11::kanMX4 [pRS416-LST8]
This study Fig. 3B
SH100 (WT) MATa leu2-3,112 ura3-52 rme1 trp1 
his4 HMLa ade2 tor2::ADE2 
[YCplac111::TOR2] 
(57) Fig. 3C, 4, 
5D, 6A, 
6B, 6C, 
Table 1
SH121 (tor2-
21) 
MATa leu2-3,112 ura3-52 rme1 trp1 
his4 HMLa ade2 tor2::ADE2 
[YCplac111::tor2-21] 
Fig. 3C, 4, 
5D, 6B, 
6C, Table 
1 
SH221 (tor1 
tor2-21) 
MATa leu2-3,112 ura3-52 rme1 trp1 
his3 HMLa ade2 tor1::HIS3 
tor2::ADE2 [YCplac111::tor2-21]
 
TPY157 
(tor2-21 far3) 
SH121 far3::kanMX4 This study Fig. 3C
TPY147 
(tor2-21 far7) 
SH121 far7::kanMX4 This study Fig. 3C
TPY213 
(tor2-21 far8) 
SH121 far8::kanMX4 This study Fig. 3C
TPY207 
(tor2-21 far9) 
SH121 far9::kanMX4 This study Fig. 3C
TPY151 
(tor2-21 
far10) 
SH121 far10::kanMX4 This study Fig. 3C
TPY116 
(tor2-21 
far11) 
SH121 far11::kanMX4 This study Fig. 3C, 
4C, 6B 
TPY110 
(tor2-21 sac7) 
SH121 sac7::kanMX4 This study Fig. 4A, 
4C, 6B. 
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Table 1
TPY311 
(tor2-21 
far11) 
SH121 far11::TRP1 This study Fig. 4C, 
4D, Table 
1 
TPY301 
(tor2-21 sac7 
far11) 
SH121 sac7::kanMX4 far11::TRP1 This study Fig. 4C, 
Table 1 
TPY680 
(tor2-21 far11 
rom2) 
SH121 rom2::kanMX4 far11::TRP1 This study Fig. 4D
BY4741 MATa ura3 leu2 his3 met15 Yeast Genome 
Deletion Project 
 
BY4741 far11 BY4741 far11::kanMX4 Fig. 5A
TPY633 BY4741 tpd3::kanMX4 far11::HIS3 This study Fig. 5A
TPY632 BY4741 pph21::kanMX4 
pph22::kanMX4 far11::HIS3
This study Fig. 5A
TPY625 (lst8 
tpd3) 
MATα ura3 leu2 lys2 lst8::LEU2 
tpd3::kanMX4 [pRS416-LST8]
This study Fig. 5B
TPY648 (lst8 
rts1) 
MATα ura3 leu2 lys2 lst8::LEU2 
rts1::kanMX4 [pRS416-LST8]
This study Fig. 5B
TPY732 (lst8 
cdc55) 
MATα ura3 leu2 lys2 lst8::LEU2 
cdc55::kanMX4 [pRS416-LST8]
This study Fig. 5B
BY4741 (WT) MATa ura3 leu2 his3 met15 [pRS416] This study Fig. 5C
BY4741 (lst8) MATa ura3 leu2 his3 met15 
lst8::LEU2 [pRS416-LST8]
This study Fig. 5C
BY4741 
(pph21/22) 
MATa ura3 leu2 his3 met15 
pph21::kanMX4 
pph22::kanMX4[pRS416-LST8]
This study Fig. 5C
TPY622 (lst8 
pph21/22) 
MATa ura3 leu2 his3 met15 
lst8::LEU2 pph21::kanMX4 
pph22::kanMX4[pRS416-LST8]
This study Fig. 5C
TPY665 (rts1) MATa leu2-3,112 ura3-52 rme1 trp1 
his4 HMLa ade2 tor2::ADE2 
rts1::kanMX4 [YCplac111::TOR2]
This study Fig. 5D, 
6C 
TPY601 
(tor2-21 rts1) 
MATa leu2-3,112 ura3-52 rme1 trp1 
his4 HMLa ade2 tor2::ADE2 
rts1::kanMX4 [YCplac111::tor2-21]
This study Fig. 5D, 
6C 
TB50a MATa leu2–3,112 ura3–52 trp1 his3 
rme1 HMLa 
(126) Fig. 7 
SW70 TB50a 3HA-TOR2 Fig. 7 
TPY1246 TB50a 3HA-TOR2 sac7::HIS3 This study Fig. 7 
TPY1249 TB50a 3HA-TOR2 far11::TRP1 This study Fig. 7 
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Table 3.  Plasmids used in Chapter 2 
Plasmid Description Reference Application 
pZL2422 pRS416-SAC7 This study Fig. 1
pZL2550 pRS416-FAR11 This study Fig. 1
pZL1255 pRS412-LST8 This study Fig. 2A-B
pZL2762 pRS416-FAR11-HA, expressing Far11 
from its own promoter with a 3xHA tag 
at the C-terminus. 
This study Fig. 3A, 5A
pTP242 pRS415-ADH1-TPD3-myc, expressing 
Tpd3 from the ADH1 promoter with a 
3xmyc tag at the C-terminus.
This study Fig. 5A
pTP244 pRS415-PPH21-myc, expressing 
Pph21 from its own promoter with a 
3xmyc tag at the C-terminus.
This study Fig. 5A
pZL339 pRS416-LST8  (77) Fig. 3B, 5B
pTP311 pRS416-SLM1-HA, expressing Slm1 
from its own promoter with a 3xHA tag 
at the C-terminus.
This study Fig. 6A
pTP377 pRS416-SLM2-HA, expressing Slm2 
from its own promoter with a 3xHA tag 
at the C-terminus.
This study Fig. 6
pTP271 pRS416-YPK2-HA, expressing Ypk2 
from its own promoter with a 3xHA tag 
at the C-terminus.
This study Fig. 6 
pZL3031 pET24a-SLM1, expressing Slm1 with 
a C-terminal 6xHis tag under the 
control of an IPTG-inducible promoter. 
This study Fig. 7 
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CHAPTER 3. TIERED ASSEMBLY OF THE  
YEAST FAR3-7-8-9-10-11 COMPLEX AT THE  
ENDOPLASMIC RETICULUM     
3.1. Summary 
TOR (target of rapamycin) signaling is a conserved, essential pathway 
integrating nutritional cues with cell growth and proliferation. The TOR kinase exists in 
two distinct complexes, TORC1 and TORC2. It has been reported that protein 
phosphatase 2A (PP2A) and the Far3-7-8-9-10-11 complex (Far complex) negatively 
regulate TORC2 signaling in yeast. The Far complex, originally identified as factors 
required for pheromone-induced cell cycle arrest, and PP2A form the yeast counterpart 
of the STRIPAK complex, which was first isolated in mammals. The cellular localization 
of the Far complex has yet to be fully characterized. Here I show that the Far complex 
localizes to the endoplasmic reticulum (ER) by analyzing functional, GFP-tagged Far 
proteins in vivo. I found that Far9 and Far10, two homologous proteins each with a tail-
anchor domain, localize to the ER in mutant cells lacking the other Far complex 
components. Far3, Far7, and Far8 form a subcomplex, which is recruited to the ER by 
Far9/10. The Far3-7-8 complex in turn recruits Far11 to the ER. Finally, I show that the 
tail-anchor domain of Far9 is required for its optimal function in TORC2 signaling. My 
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study reveals tiered assembly of the yeast Far complex at the ER and a function for Far 
complex’s ER localization in TORC2 signaling. 
3.2. Introduction 
Protein phosphorylation plays important roles in many cellular processes. 
Protein phosphorylation is catalyzed by specific protein kinases and protein 
dephosphorylation is carried out by protein phosphatases. Thus, the phosphorylation 
state of proteins is finely controlled by the opposing activities of protein kinases and 
phosphatases. Multiple mechanisms exist to fine-tune the activity of these protein 
kinases and phosphatases through the regulation of their expression levels, their 
activity, cellular localization, and availability to substrates, among others. Recently, a 
large multi-protein complex known as the striatin-interacting phosphatase and kinase 
(STRIPAK) complex was found in mammals. STRIPAK contains PP2A catalytic and 
scaffolding subunits, striatins, the striatin-associated protein Mob3, two homologous 
novel proteins STRIP1 and STRIP2, members of the germinal center kinase III family of 
Ste20 kinases, and the Cerebral Cavernous Malformation 3 (CCM3) protein (48, 96). The 
STRIPAK assembly maintains mutually exclusive interactions with either the CTTNBP2 
(cortactin-binding protein 2) proteins or a second subcomplex consisting of 
sarcolemmal membrane-associated protein (SLMAP) and two related coiled-coil 
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proteins SIKE and FGFR1OP2. The N-terminal region of CCM3 mediates 
heterodimerization with Ste20 kinases, and its C-terminal domain interacts with striatin 
(24, 39, 67, 75, 131), which also interacts with the regulatory and catalytic subunits of 
PP2A, thus bridging a kinase to a phosphatase. This arrangement likely facilitates the 
regulation of the activity of protein kinases by PP2A (47, 67). Both Striatin 3 and STRIP1 
localize to the Golgi and depletion of either results in similar defects suggesting they 
perform similar functions in regulation of Golgi morphology and mitosis (42, 67). The 
SLMAP gene has several splice variants, encoding tail-anchored membrane proteins 
that associate with the sarcolemmal membrane in muscle cells, the endoplasmic 
reticulum and the mitochondrial membrane in non-muscle cells, and the centrosome 
and the outer nuclear envelope (21, 42, 52, 89, 124). SLMAP is required for myoblast 
fusion, centrosome function, and structural arrangement of the excitation-contraction 
coupling apparatus in cardiomyocytes (42, 51-53). Much remains to be determined 
about the role of STRIPAK components and the regulation and substrates of STRIPAK. 
Orthologs of mammalian STRIPAK components have been reported to exist in 
many eukaryotes. The Drosophila STRIPAK complex has been reported to be involved in 
Hippo signaling by mediating phosphorylation of the Hippo kinase and the 
transcriptional activator Yorkie (96).  In Neurospora crassa, orthologs of STRIPAK 
complex components are required for hyphal fusion (108, 127). In the ascomycete 
  
79 
 
Sordaria macrospora, the STRIPAK complex is required for sexual development and 
vegetative hyphal fusion (14, 15). In the fission yeast Schizosaccharomyces pombe, 
components of the STRIPAK complex localize to the mitotic spindle pole body in early 
mitosis and are required for the establishment of asymmetry of the septation initiation 
network, a conserved signaling pathway that is required for cytokinesis and mitotic 
transitions (42, 109).  
In the budding yeast Saccharomyces cerevisiae, the STRIPAK complex has been 
reported to mediate pheromone signaling, the TORC2 signaling pathway, and the 
toxicity due to expression of human Caspase-10 in yeast (7, 68, 76, 93). The yeast 
STRIPAK complex contains Far3, Far7, Far8, Far9, Far10, Far11, Tpd3 (the A scaffolding 
subunit of PP2A), and Pph21/22 (the two redundant catalytic subunits of PP2A) (68, 73, 
76, 93, 119). Far11 is an ortholog of human STRIP1/2; Far8 shares limited sequence 
similarity to human striatins; Far9 and Far10 are homologous tail-anchored proteins 
similar to human SLMAP (Table 1) (9, 48). Yeast cells secrete pheromones to induce cell 
cycle arrest to prepare for mating as part of the fungal life cycle (38). Mutations in FAR 
genes lead to increased resistance to pheromone-induced cell cycle arrest (59, 68), but 
the underlying mechanism is still unclear. TOR (target of rapamycin) kinases are 
conserved in eukaryotes and exist in two distinct multi-protein complexes, TORC1 and 
TORC2 (74, 80), and mutations in the yeast STRIPAK complex components lead to 
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suppression of cell lethality specifically due to TORC2-deficiency possibly by restoring 
phosphorylation of TORC2 substrates Slm1, Slm2, Ypk1 and Ypk2 (7, 37, 90, 93). The 
role of STRIPAK in human Caspase-10 induced toxicity in yeast likely results from 
promoting Atg13 dephosphorylation and subsequent activation of autophagy (65, 76).  
In yeast, Far3, Far7, Far8, Far9, Far10 and Far11 have been reported to form a 
complex (68, 73, 93). However, it is unclear how these proteins assemble together to 
form the final complex, and identification of the cellular component of this complex 
could potentially provide insights into the mechanism of its function. Cellular 
localization of subsets of the Far complex components has been reported in three 
different studies, however the results were not consistent (9, 61, 76). A genome-wide 
study on the localization of yeast proteins found that Far3, Far7, and Far8 localize to the 
ER (61). In that study, Far9 was shown to be localized in the cytoplasm, Far10 
localization was ambiguous, and there was no data on Far11. In another study, Beilharz 
et al. showed that Far9 localizes to the ER and that Far10 is found in clusters within the 
bounds of the ER (9). In the third reported study on the localization of Far proteins, 
Far11 was reported to co-localize with Chc1, a late-Golgi protein, Far3 with Cop1, an 
early Golgi protein, and Far9 with Sec13, an ER-to-Golgi protein that is located on ER-
derived transport vesicles (76). To gain insights into how the Far proteins assemble into 
a complex and address the inconsistency in their cellular localization, I constructed 
  
81 
 
functional GFP-tagged Far proteins and analyzed their localization in various far 
mutants. My data show that all of the Far proteins localize in a tiered fashion at the 
endoplasmic reticulum and ER localization of Far9 is required for its optimal function in 
TORC2 signaling. 
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Table 1.  Components of the STRIPAK complex in mammals and yeast 
Description Mammals Yeast 
PP2A A subunit PR65A/PR65B Tpd3 
PP2A B”’ subunit Striatin/ Striatin-3/ 
Striatin-4 
Far8 
PP2A C subunit PP2A Cα and Cβ Pph21, Pph22 
Novel protein STRIP1/STRIP2 Far11 
Tail-anchored protein SLMAP Far9/Far10 
Coiled-coil domain protein SIKE, FGFR1OP2 Far3, Far7 
Striatin-associated protein Mob3 Mob1 
Ste20 family kinase STK24/STK25/Mst4 Kic1 
Cavernous cerebral 
malformation protein 3 
CCM3 ? 
Cortactin-binding protein 2 CTTNBP2 ? 
(Proteins in italics are orthologs of the respective mammalian proteins but 
 have not yet been confirmed to be part of the yeast STRIPAK complex) 
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3.3. Materials and methods 
3.3.1. Strains, plasmids, and growth media and growth conditions 
Yeast strains and plasmids used in this study are listed in Table 2 and 3, 
respectively. Yeast cells were grown in SD (0.67% yeast nitrogen base plus 2% dextrose),  
YNBcasD (SD medium plus 1% casamino acids), or YPD (1% yeast extract, 2% peptone, 
2% dextrose) medium at temperatures as indicated in the text and in the figure legends. 
When necessary, amino acids, adenine, and/or uracil were added to the growth medium 
at standard concentrations to cover auxotrophic requirements (2). 
3.3.2.  Cellular extract preparation and co-immunoprecipitation 
Total cellular protein extracts were prepared by disrupting yeast cells in 
extraction buffer (1.85 N NaOH–7.5% β-mercaptoethanol) followed by precipitation 
with trichloroacetic acid as described (129). For co-immunoprecipitation experiments, 
cellular lysates were prepared in IP buffer (50 mM Tris-HCl pH 7.6, 150 mM NaCl, 0.5% 
Triton X-100, and protease inhibitors). Cell extracts (~3 mg proteins) were incubated at 4 
°C for 1 h with anti-myc antibody (9E10, Roche) or anti-HA antibody (12CA5, Roche) as 
indicated, after which 30 µl of a 50% slurry of protein G-Sepharose (Roche) was added 
to each sample and the samples were further incubated at 4 °C for 2 h. Washed 
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immunoprecipitates bound to the Sepharose beads were released by boiling in 1X SDS-
PAGE loading buffer. The released immune complexes were analyzed by SDS-PAGE 
and immunoblotting. myc, HA, and GFP-tagged proteins were probed with anti-myc 
antibody 9E10, high affinity anti-HA antibody 3F10 (Roche),  and anti-GFP antibody B-2 
(Santa Cruz Biotechnology, Inc), respectively. Chemiluminescence images of Western 
blots were captured using the Bio-Rad Chemi-Doc photo documentation system (Bio-
Rad) and processed using Bio-Rad Quantity One software. Experiments were repeated 
at least twice.     
3.3.3.  Fluorescence microscopy 
Fluorescence of GFP and RFP-tagged proteins was analyzed in live cells grown 
in SD medium to the mid-logarithmic growth phase by fluorescence microscopy. Cells 
were concentrated by centrifugation at 5000g for 2 minutes and fluorescence images 
were immediately captured using a Nikon Eclipse E800 microscope equipped with an 
HBO 100 W/2 mercury arc lamp, a Nikon Plan Fluor 100x objective lens, a Photometrics 
Coolsnap fx CCD camera, and a Nikon B-2E/C filter set (excitation light wavelengths 
465-495 nm, emission light wavelengths 515-555 nm, dichromatic mirror cut-on 
wavelength 505 nm) for GFP images and a Y-2E/C filter set (excitation light 
wavelengths 540-580 nm, emission light wavelengths 600-660 nm, dichromatic mirror 
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cut-on wavelength 595 nm) for RFP images. Digital images were acquired using the 
Metamorph Imaging Software and processed using ImageJ (NIH) and Adobe 
Photoshop software. Experiments were repeated at least twice. 
3.3.4. Pheromone response halo assay 
Sensitivity to the mating pheromone α-factor was assayed by standard plate halo 
assays as previously described (59, 111). Briefly, 2 µg of α-factor was applied to a sterile 
filter paper disc placed onto a lawn of 1x106 cells spread on a YNBcasD plate. Halo 
formation was documented after 3 days of cell growth. Experiments were repeated at 
least twice. 
3.4.  Results 
3.4.1.  GFP-tagged Far3, Far7, Far8, Far9, Far10, and Far11 localize to the 
Endoplasmic Reticulum   
Elucidating the cellular localization of the Far Complex thus far has not been 
straight forward. Several studies report inconsistent data with the components of the 
Far complex localizing to different cellular compartments from one study to the next (9, 
61, 76). Furthermore, none of the studies comprehensively analyzed the intracellular 
localization of all components of the complex. In all cases, fluorescent tags were fused to 
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each Far protein to localize each component. I considered two possibilities that could 
result in disparity of the cellular localization patterns of the Far proteins and designed 
the experiment to minimize these complications. First, the functionality of a protein can 
be inhibited by the addition of a tag. Therefore functionality of the fusion proteins 
should be determined. The functionality of the fusions of the previous studies was not 
indicated therefore, it is possible that if their functionalities were not tested and the 
fusions were not functional the proteins could show inconsistent cellular localizations. 
Another factor that could affect the localization of a fusion protein is the placement of 
the fluorescent tag. For instance, Far9 and Far10 contain a hydrophobic tail-anchor 
domain, and the addition of a fluorescent protein at the C-terminal end of Far9 and 
Far10 would affect their cellular localization. Therefore, differential cellular localization 
of Far9 and Far10 could be attributed to the position of the fluorescent protein tag such 
as in Lisa-Sanatmaria et al.’s study where the authors added a C-terminal CFP tag to 
Far9 and found Far9 to localize on transport vesicles between ER and the Golgi 
inconsistent with previous studies (9, 61). Accordingly, I generated N-terminal GFP-
tagged Far9 and Far10 fusion constructs and C-terminal GFP-tagged Far3, Far7, Far8 
and Far11 constructs on centromeric plasmids and determined their functionality and 
cellular localization. Expression of GFP-tagged Far3, Far7, Far8 and Far11 fusion 
proteins was under the control of their respective endogenous promoters. Expression of 
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GFP-tagged Far9 and Far10 was under the control of a stronger but still relatively weak 
promoter of MKS1 (105) due to my initial observations that N-terminal GFP-tagged Far9 
and Far10 under the control of their endogenous promoters did not yield enough signal 
to determine their cellular localization. To minimize potential interference of GFP with 
the functionality and thus localization of Far proteins, I also introduced a 10-alanine 
linker between the Far proteins and the GFP tag.   
I first determined the functionality of GFP-tagged Far fusion proteins by a plate 
halo assay (Fig. 1A). Wild-type mating type a cells normally arrest cell growth around a 
paper disc infused with α-factor and create a cell-free zone in the shape of a halo. I 
generated far3, far7, far8, far9, far10, and far11 single deletion mutants and found that 
they became resistant to α-factor-induced cell cycle arrest, which was manifested by 
increased cell growth around the disc containing α-factor, consistent with previous 
results (68).  After these farΔ mutants were transformed with centromeric plasmids 
encoding respective wild-type FAR genes tagged with GFP, the resultant transformants 
now became as sensitive to α-factor as wild-type cells, indicating that GFP-tagged Far3, 
Far7, Far8, Far9, Far10, and Far11 proteins were all functional.  
 I next examined the cellular localization of the GFP-tagged Far proteins in their 
respective far deletion mutant strains. The right column of Figure 1B shows that all 
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exhibited localizations suggestive of perinuclear and periplasmic endoplasmic 
reticulum (ER) localization. To support this assumption, in cells expressing GFP-tagged 
Far proteins, I coexpressed C-terminal red fluorescent protein (RFP)-tagged Shr3, an 
ER-localized chaperone for packaging amino acid permeases into COPII-coated 
transport vesicles (71). Figure 1B shows that Shr3-RFP and each of the six Far-GFP 
fusion proteins colocalize, indicating that the Far complex localizes to the ER. I 
expressed GFP-tagged Far proteins in respective far deletion mutant strains of two other 
strain backgrounds, BY4741, which is derived from S288c, and SY2227 (68), and I found 
that in these strains, GFP-tagged Far proteins also localized to the ER (data not shown), 
indicating that ER localization of the Far complex is not strain dependent. 
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Figure 1.  The Far3,7,8,9,10,11 complex localizes to the ER.  
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(A) GFP-tagged FAR constructs complement respective far deletion mutations by halo 
assay. Wild-type (WT, SY2227) and isogenic farΔ mutant cells (far3Δ, TPY1010; far7Δ, 
TPY1013; far8Δ, TPY1015; far9Δ,  TPY1048; far10Δ, TPY1072; far11Δ, SY4064) carrying the 
empty vector pRS416 (Vector) or plasmids encoding respective FAR-GFP fusions (FAR3-
GFP, pTP143; FAR7-GFP, pTP164; FAR8-GFP, pTP131; GFP-FAR9, pTP179; GFP-FAR10, 
pTP203; FAR11-GFP, pZL2564) were grown on YNBcasD medium  in the presence of a 
paper filter disc containing α-factor as described in experimental procedures.  
(B) Colocalization of GFP-tagged Far proteins with ER-localized Shr3-RFP.  farΔ mutant 
cells (far3Δ, TPY157; far7Δ, TPY147; far8Δ, TPY213; far9Δ, TPY357; far10Δ, TPY151; 
far11Δ, TPY116) coexpressing respective GFP-tagged Far proteins as described for panel 
(A) and RFP-tagged Shr3 (pTP201) were grown in SD medium and observed by 
fluorescence microscopy. GFP and RFP fluorescence images were captured and 
processed using the same parameters for each channel. Vacuolar autofluorescence in the 
RFP channel was sometimes observed.  
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3.4.2. Far9 and Far10 localize to the ER independently of the other Far proteins 
To better understand how the Far complex is organized on the ER, I sought to 
determine which Far protein(s) establishes a foothold on the ER. To this end, I analyzed 
the cellular localization of individual GFP-tagged Far proteins in a far3/7/8/9/10/11Δ 
sextuple mutant strain. Figure 2 shows that Far3-GFP, Far7-GFP, Far8-GFP, and Far11-
GFP, when expressed individually in the sextuple mutant strain, did not exhibit ER 
localization, indicating that they were unable to localize to the ER in the absence of 
other Far complex components. In contrast, GFP-Far9 and GFP-Far10 fusion proteins 
could still localize to the ER in the sextuple mutant, indicating that Far9 and Far10 
establish ER localization for the complex. Far9 and Far10 contain a tail-anchor domain 
at their C-termini. Therefore, it is not surprising that they may function as the ER 
anchor for the Far complex. Furthermore, the localization of Far9 and Far10 on the ER 
when expressed individually in the sextuple mutant suggests that these two 
homologous proteins do not require hetero-oligomerization for ER recruitment. 
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Figure 2.  Far9 and Far10, but not Far3, Far7, Far8 or Far11, are able to localize to the ER 
in the absence of the other Far complex components.    
Sextuple farΔ mutant cells (TPY845) expressing GFP-tagged Far proteins as indicated 
were grown in SD medium and observed by fluorescence microscopy. 
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3.4.3. Tiered assembly of the components of the Far complex at the ER 
To further characterize the organization of the Far complex on the ER, I sought to 
determine the order in which the rest of the complex localizes to the ER. To achieve this, 
I determined whether ER localization of GFP-tagged Far3, Far7, Far8, or Far11 could be 
altered by the absence of just one of the other five Far complex components. 
Accordingly, I characterized the cellular localization of Far3-GFP in far3Δ far7Δ, far3Δ 
far8Δ, far3Δ far9Δ, far3Δ far10Δ, and far3Δ far11Δ double deletion mutant cells. Far3-GFP 
localization at the ER was abolished by far7Δ, far8Δ, far9Δ, and far10Δ mutations but still 
showed normal ER localization in a far11Δ mutant, indicating that ER localization of 
Far3-GFP requires Far7, Far8, Far9 and Far10, but not Far11 (Fig. 3A). Using the same 
strategy, I determined the cellular localization of Far7-GFP, Far8-GFP, and Far11-GFP in 
respective double deletion mutant cells. Likewise, ER localization of Far7-GFP and Far8-
GFP was abolished by all respective farΔ mutations except a far11Δ mutation (Fig. 3B-C). 
Interestingly, ER localization of Far11-GFP was disrupted by the deletion of any of the 
other five Far complex components (Fig. 3D), suggesting that Far11 is the most 
peripheral component of this complex at the ER. These data also suggest that Far3, Far7, 
Far8, and Far11 are peripheral membrane proteins since their ER localization requires 
the tail-anchored proteins Far9 and Far10. This possibility was supported by my initial 
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observation early in my studies that the localization of GFP-tagged Far3, Far7, Far8, and 
Far11 became more cytoplasmic when they were expressed in wild-type cells in 
comparison to respective deletion mutant cells, suggesting that these four GFP-tagged 
Far proteins compete with their non-tagged counterparts for Far9/10-dependent ER 
localization (data not shown). The interdependence of Far3, Far7, and Far8 for ER 
localization also suggests that they might form a subcomplex before their ER 
recruitment. Together, these data suggest that the Far complex assembles at the ER in 
the spatial order of Far9/10, Far3/7/8, and then Far11. 
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Figure 3.  Cellular localization of GFP-tagged Far3, Far7, Far8 or Far11 in the absence of 
individual components of the Far complex.   
(A) Localization of Far3-GFP in the mutant strains as indicated (far3Δ, TPY1010; far3Δ 
far7Δ, TPY1358; far3Δ far8Δ, TPY1361; far3Δ far9Δ, TPY1348; far3Δ far10Δ, TPY1363; far3Δ 
far11Δ  TPY1402).  (B) Localization of Far7-GFP in the mutant strains as indicated (far7Δ, 
TPY1013; far7Δ far3Δ, TPY1408; far7Δ far8Δ, TPY1366; far7Δ far9Δ, TPY1350; far7Δ far10Δ, 
TPY1368; far7Δ far11Δ TPY1352). (C) Localization of Far8-GFP in the mutant strains as 
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indicated (far8Δ, TPY1015; far8Δ far3Δ, TPY1369; far8Δ far7Δ, TPY1370; far8Δ far9Δ, 
TPY1351; far8Δ far10Δ, TPY1373; far8Δ far11Δ TPY1405). (D) Localization of Far11-GFP in 
the mutant strains as indicated (far11Δ, SY4064; far11Δ far3Δ, TPY1374; far11Δ far7Δ, 
TPY1377; far11Δ far8Δ, TPY1406; far11Δ far9Δ, TPY1410; far11Δ far10Δ, TPY1379). All cells 
were grown in SD medium and observed by fluorescence microscopy. 
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3.4.4. Far3, Far7, and Far8 form a subcomplex 
To test whether Far3, Far7, and Far8 are able to form a subcomplex independent 
of Far9, Far10 and Far11, I determined whether Far3, Far7 and Far8 could form pair-
wise interactions in far3/7/8/9/10/11Δ sextuple mutant cells by co-immunoprecipitation. 
Accordingly, Far3-GFP was coexpressed with either 3xHA epitope-tagged Far7 or Far8 
and Far7-GFP was coexpressed with either 3xHA epitope-tagged Far3 or Far8 in 
far3/7/8/9/10/11Δ sextuple mutant cells. HA-tagged proteins from cell lysates were 
immunoprecipitated with anti-HA antibody and immunoprecipitates were probed with 
anti-GFP antibody to detect GFP-tagged proteins via Western blotting. I found that 
Far7-HA, but not Far8-HA, was able to pull down Far3-GFP (Fig. 4A, lane 1-3). 
Similarly, Far3-HA, but not Far8-HA, was able to pull down Far7-GFP (Fig. 4A, lane 4-
6). Together, these data indicate that Far3 and Far7 are able to interact with each other 
in the absence of the other Far complex components.  
Far8 has been reported to interact with Far3 and Far7 by yeast two-hybrid and 
co-immunoprecipitation analyses in wild-type strains (68, 73). Although I carried out 
the interaction analysis between Far8 and Far3 or Far7 in sextuple mutant cells, which 
were not used in previous studies, the failure to detect their interactions in such cells 
was still surprising because these three proteins appear to require each other to for ER 
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localization as shown in Figure 3. One possibility is that Far8 may only bind to the Far3-
7 complex. To test this hypothesis, I first confirmed whether Far8 interacts with Far3 or 
Far7 in respective double deletion mutant cells. I generated a far3Δ far8Δ double mutant 
carrying plasmids encoding FAR3-HA and FAR8-GFP. Figure 4B shows that Far8-GFP 
was co-immunoprecipitated specifically with Far3-HA (compare lane 1 and 2). 
Similarly, I found that Far8-GFP specifically interacts with Far7-HA in a far7Δ far8Δ 
double mutant (Fig. 4B, lane 3-4). I next examined whether Far8 interacts with the Far3-
Far7 complex in the sextuple mutant. I coexpressed Far3-HA, Far8-GFP and non-tagged 
Far7 in far3/7/8/9/10/11Δ sextuple mutant cells and found that expression of Far7 in the 
sextuple mutant was sufficient for Far3-HA to interact with Far8-GFP (Fig. 4C, compare 
lane 1-2). Similarly, reintroduction of Far3 into sextuple mutant cells coexpressing Far7-
HA and Far8-GFP also enabled an interaction between Far7 and Far8 (Fig. 4C, compare 
lane 3-4). These data together indicate that Far3, Far7, and Far8 form a subcomplex in 
the absence of the other components of the Far complex. 
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Figure 4.  Far3, Far7, and Far8 form a subcomplex.  
 (A) Far3 and Far7 are able to interact in the absence of Far8, Far9, Far10, and Far11. Cell 
lysates of sextuple farΔ mutant cells (TPY845) coexpressing Far3-GFP (pTP143) and 
Far7-HA (pTP646) or Far8-HA (pTP658), Far7-GFP (pTP164) and Far3-HA (pTP655) or 
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Far8-HA (pTP658) as indicated were subjected to immunoprecipitation with anti-HA 
antibody and epitope-tagged proteins were detected by immunoblotting.  * and ** 
indicate the heavy chain of the anti-HA antibody used for immunoprecipitation that 
was detected by goat anti-mouse IgG light chain specific and standard secondary 
antibody, respectively.  
(B) Far8 interacts with Far3 or Far7 in the presence of the other Far complex 
components. far3/8Δ mutant cells expressing Far8-GFP (TPY1369) without or with Far3-
HA and far7/8Δ mutant cells expressing Far8-GFP (TPY1370) without or with Far7-HA 
were analyzed for interactions between Far8-GFP and Far3-HA or Far7-HA by 
immunoprecipitation and immunoblotting.  
(C) Far8 interacts with the Far3-7 complex. Cell lysates of sextuple farΔ mutant cells 
expressing epitope-tagged and non-tagged proteins as indicated were subjected to 
immunoprecipitation with anti-HA antibody. GFP- and HA- tagged proteins were 
detected by immunoblotting. 
(D) Model of assembly of the Far3-7-8 subcomplex. 
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3.4.5. Interaction between Far9 and Far11 requires the Far3-7-8 subcomplex 
ER localization of Far11-GFP was disrupted by deletion of any of the other Far 
complex components as shown in Figure 3D. These findings along with the findings 
that Far3, Far7, and Far8 form a subcomplex suggest that the Far3-7-8 subcomplex may 
bridge the interaction of Far11 and Far9/10 at the ER. To test this possibility, interaction 
between myc-tagged Far9 and HA-tagged Far11 was analyzed in far9Δ far11Δ double 
mutant cells without (WT) or with an additional mutation of far3Δ, far7Δ, or far8Δ. Far9-
myc was immunoprecipitated from cell lysates and immunoprecipitates were probed 
with anti-HA antibody to detect Far11-HA via Western blotting. Figure 5 shows that 
Far11-HA was co-immunoprecipitated with Far9-myc and deletion of FAR3, FAR7, or 
FAR8 greatly reduced their interaction. This data indicates that ER recruitment of Far11 
by Far9 requires the Far3-7-8 subcomplex. 
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Figure 5.  Interaction between Far9 and Far11 is greatly reduced in the absence of Far3, 
Far7, or Far8.  
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(A) Cell lysates of strains TPY1411 (WT), TPY1412 (far3Δ), TPY1413 (far7Δ), and 
TPY1416 (far8Δ) coexpressing Far9-myc and Far11-HA (pZL2762) and the strain SY4064 
(WT) expressing Far11-HA alone were subjected to immunoprecipitation with anti-myc 
antibody. HA- and myc-tagged proteins were detected by immunoblotting. An asterisk 
denotes a proteolytic product of Far11-HA (93). 
(B) Model depicting interaction between Far11 and Far9 in wildtype versus far3Δ far7Δ 
or far8Δ mutants. 
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3.4.6.  ER localization of Far9 is required for its optimal function in TORC2 
signaling 
Yeast Far9 and Far10 and their human and fly orthologs all contain a tail-anchor 
domain and a forkhead-associated (FHA) domain (Fig. 6A). Tail-anchored proteins 
utilize the tail-anchor domain for membrane association (17). The finding that Far9 and 
Far10 are able to localize to the ER in the absence of the other Far complex components 
prompted us to determine the role of Far9’s tail-anchor in the ER localization of Far9. 
Accordingly, I constructed a GFP-tagged C-terminal truncation mutant of Far9, GFP-
Far9ΔC and examined its location in far9Δ mutant cells. Unlike GFP-tagged wild-type 
Far9, GFP-Far9ΔC localized diffusely in the cytoplasm (Fig. 6B), indicating that the tail-
anchor domain of Far9 is required for its ER localization.  
Recently, I proposed that the Far complex antagonizes TORC2 signaling by 
showing that a far9Δ mutation or loss of other Far complex components are able to 
bypass a tor2 temperature sensitive (tor2-21) mutation (93). I sought to test whether ER 
localization of the Far complex is required for its function. To that end, I introduced a 
far9ΔC mutation, which results in the synthesis of Far9 without the tail-anchored 
domain, at the genomic FAR9 locus in tor2-21 mutant cells. I then tested whether the 
far9ΔC mutation could bypass the tor2-21 mutation and found that far9ΔC was able to 
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partially mimic far9Δ in suppressing the growth defect of tor2-21 mutant cells grown at 
36 °C and 37 °C (Fig. 6C). To exclude the possibility that the removal of the tail anchor 
domain of Far9 may reduce the steady-state level of Far9 by reducing its stability, which 
could explain the partial suppression of the tor2-21 growth defect at high temperatures, 
I examined the levels of GFP-tagged Far9 and Far9ΔC in tor2-21 far9Δ cells and found 
that Far9ΔC was expressed to similar levels as full length Far9 (Fig. 6D). Together these 
data suggest that the suppression of the tor2-21 mutation by far9ΔC results from the loss 
of ER localization of Far9 and that ER localization of Far9 is required for its optimal 
function.  
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Figure 6.  The tail-anchor domain of Far9 is required for its ER localization.  
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(A) Diagrammatic representations of Far9 and its orthologs in flies and humans. A 
conserved FHA domain and the tail-anchor domain are indicated by gray and white 
rectangles, respectively.  
(B) ER Localization of Far9 requires the tail-anchor domain. far9Δ mutant cells 
(TPY1048) expressing GFP-tagged Far9 (pTP179) or Far9ΔC (pTP554) were grown in SD 
medium and observed by fluorescence microscopy.  
(C) The tail-anchor domain of Far9 is required for the optimal function of Far9 in 
TORC2 signaling. Serial dilutions of indicated cells (WT, SH100; tor2-21, SH121; tor2-21 
far9Δ, TPY357; tor2-21 far9ΔC, TPY1341) were grown on YPD medium at 30 °C, 36 °C, 
and 37 °C for 3-4 days.  
(D) Loss of the tail-anchor domain of Far9 does not reduce its steady-state level. Total 
cellular proteins of far9Δ mutant cells (TPY357) expressing GFP-Far9 or GFP-Far9ΔC 
were prepared and separated by SDS-PAGE and GFP-tagged proteins were detected by 
immunoblotting. 3-Phosphoglycerate kinase (Pgk1) was included as a loading control. 
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3.5.  Discussion 
3.5.1. ER/nuclear envelope localization of STRIPAK complex components: a 
universal theme 
The Far complex is part of the yeast striatin interacting phosphatase and kinase 
(STRIPAK) complex which is conserved in eukaryotes (14, 42, 48, 67, 93, 96). Cellular 
localization of the Far complex proteins has been reported previously (9, 61, 76). 
However, these studies report some inconsistent and conflicting results.  While 
consistent with data from a genome-wide study on the localization of yeast proteins 
and a study on cellular localization of tail-anchored proteins showing ER localization of 
Far3, Far7, and Far8, and Far9, and Far10 (9, 61), this study provides a comprehensive 
look into the localization of the Far Complex at the ER including the order of assembly 
of the complex in an effort to rectify the discrepancies. Using fluorescence microscopy, I 
found that functional Far-GFP fusions localize to the nuclear and plasma membrane 
periphery indicative of endoplasmic reticulum localization. Co-localization of the Far-
GFP fusions with the ER packaging chaperone Shr3-RFP tagged protein confirm ER 
localization of the Far complex. By systematically examining the localization of Far-GFP 
fusions in sextuple far3/7/8/9/10/11Δ and various double farΔ mutant cells I determined 
the order by which the Far complex organizes itself on the ER: Far9/10 establish a foot 
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hold on the ER utilizing the tail-anchor domain, and Far3/7/8 form a subcomplex that 
bridges Far11 to Far9/10 at the ER (Fig. 7).  
 Inconsistencies in the localization of the Far proteins in the previous studies may 
be explained by several possibilities. Cytoplasmic localization of Far9 in the genome-
wide study on yeast protein localization is most likely to be due to the tagging of GFP at 
its C-terminus, which is expected to interfere with tail-anchor domain-dependent ER 
membrane insertion of Far9. The clustering effect of Far10 in Beilharz et al.’s study may 
result from a higher level of overexpression of Far10 from the relatively strong MET25 
promoter than in my current study (78, 88). My data disagrees with Lisa-Sanatmaria et 
al.’s study, which reported Far11 as a late-Golgi protein, Far3 as an early Golgi protein, 
and Far9 on the transport vesicles between ER and the Golgi (76). Although these three 
cellular compartments are all part of the protein secretion pathway downstream of ER, 
proteins associated with these three compartments exhibit distinct cellular localization, 
different from the ER (61, 82, 85). In Lisa-Sanatmaria et al.’s study, the authors added a 
C-terminal CFP tag to Far9, failing to take into consideration the role of the tail-anchor 
domain of Far9 on its cellular localization. Furthermore, the functionality of the fusion 
proteins in the aforementioned study was not reported. If the investigators neglected to 
confirm the functionality of their fusion proteins and were in fact not functional, this 
could present another possibility that accounts for the localization differences. This 
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study has comprehensively confirmed the functionality of the Far-GFP fusion proteins 
for the analysis of their cellular localization, therefore my data showing ER localization 
of the Far complex should lie to rest the dispute over which cellular compartment the 
Far complex is associated with in yeast. 
ER/nuclear envelope localization of proteins associated with the STRIPAK 
complex seems to be a conserved feature. S. cerevisiae Far9/10 and their orthologs all 
contain a tail anchor domain at the extreme C-terminus (Fig. 6A and data not shown). 
The human ortholog of yeast Far9/10, SLMAP, has been shown to associate with the ER 
and nuclear envelope (21, 42). Two components of the STRIPAK complex in the fission 
yeast S. pombe, Csc2 (S. cerevisiae Far11 ortholog) and Csc3 (S. cerevisiae Far8 ortholog) 
also associate with the nuclear envelope/ER. Csc1, a component of the S. pombe 
STRIPAK complex and the S. cerevisiae Far9/10 ortholog, was not found to localize to the 
nuclear envelope (109). However, this could be due to the addition of GFP at its C-
terminus, which includes a tail-anchor domain. A C-terminal GFP tag is expected to 
interfere with membrane insertion of tail-anchor domain proteins. ER localization of the 
STRIPAK components appears to be important for their function: In muscle cells, 
SLMAP is associated with the sarcolemmal membrane, which is derived from the ER 
and important for muscle cell function (51, 53, 89). Here I show that ER localization of 
the Far complex is required for its optimal function in TORC2 signaling. How is ER 
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localization of the yeast Far complex required for its function in TORC2 signaling? 
Previously, I have shown that the yeast Far complex and PP2A negatively regulate 
TORC2 signaling by promoting dephosphorylation of the TORC2 substrate Slm1 and 
possibly Slm2, Ypk1 and Ypk2, all of which associate with the plasma membrane (37, 
90). The association with the Far complex could bring PP2A to the periplasmic region to 
facilitate dephosphorylation of TORC2 substrates (Fig.8).  
Unlike S. cerevisiae Far proteins, human SLMAP and the S. pombe STRIPAK 
complex also localize to the centrosome and the spindle pole body respectively (42, 52, 
109). Consistent with their localization in the centrosome/spindle pole body, the human 
and S. pombe STRIPAK complexes have been proposed to play roles in mitosis (42, 52, 
109). Failure to detect localization of the yeast Far complex components and even the 
Far9 truncation mutant without its tail-anchor domain to the spindle pole body is 
consistent with Frost et al.’s hypothesis that the function of STRIPAK complex may 
have been “repurposed” and the S. cerevisiae STRIPAK complex has lost its function in 
mitosis (42).  
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Figure 7.  Model of the assembly of the Far complex on the ER.  
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3.5.2. ER localization of the yeast Far complex has a role in TORC2 signaling 
Previously, I reported that mutations in the Far complex suppresses TORC2 
deficiency in the order: far11Δ > far8/9Δ > far3/7Δ > far10Δ (93). It is interesting to note 
that Far11, which is the most peripheral component of the complex according to this 
study, is also the most important among the six Far proteins in TORC2 signaling. 
Although this result is surprising, it may help understand why ER localization of the 
Far complex is not absolutely required for its function in TORC2 signaling. Far3 and 
Far7 are able to form a complex in the absence of the other four Far proteins. 
Coincidently, mutant effects of far3Δ and far7Δ on TORC2 signaling are most similar, 
suggesting that their roles in the Far complex are equal. Far3 and Far7 are only found in 
a restricted set of fungal species and lack apparent orthologs in animals (42). However, 
yeast Far3/Far7 and human SIKE/FGFR1OP2 are all relatively small proteins predicted 
to have a coiled-coil domain (49, 68, 73), suggesting that Far3/Far7 may be the 
functional or structural counterparts of human SIKE/FGFR1OP2. Interestingly, the 
STRIPAK complex in S. pombe contains a novel protein of 166 residues, Csc4, which is 
also predicted to have a coiled-coil domain (109). It is possible that these small, coiled-
coil domain proteins may play the same structural role in the STRIPAK complex in 
different species as a result of divergent evolution.  
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In this report, I found that Far3, Far7, and Far8 are able to form a subcomplex 
independently of Far9, Far10, and Far11. Far8 shares limited sequence homology to 
striatins, which are the B’’’ regulatory subunits of PP2A phosphatase. The PP2A 
holoenzyme in yeast is a heterotrimer consisting of the scaffolding A subunit Tpd3, the 
regulatory B subunit Cdc55 or B’ subunit Rts1, and one of the two homologous and 
functionally redundant catalytic C subunits, Pph21 or Pph22 (34). It is not clear whether 
Far8 is a B type regulatory subunit of PP2A due to my previous finding that an rts1 
mutation has a similar phenotype as mutations in the Far complex components in 
TORC2 signaling. Human Striatin 3 and its Sordaria Macrospora ortholog PRO11 have 
been reported to contain an N-terminal coiled-coil region and both proteins are critical 
components in the organization of the respective STRIPAK complexes (14, 67). Like 
human striatins, yeast Far8 was also predicted to contain an N-terminal coiled-coil 
domain (68, 73). Interestingly, almost all components of the Far complex are predicted 
to contain coiled-coil domains (68, 73). These coiled-coil domains may mediate protein-
protein interactions and provide a structural framework for the organization of the Far 
complex. Further research will be conducted to uncover the role of Far8 in the yeast 
STRIPAK complex and how the Far complex interfaces with PP2A. 
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Figure 8.  Model of PP2A-Far complex’s role in TORC2 signaling in vivo. 
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Table 2.  S. cerevisiae strains used in Chapter 3. 
Strain Genotype Source Application 
SY2227 (WT) MATa ade1-1 leu2-2,113 trp1 ura3-52 bar1 
HIS3::pFUS1::HIS3 mfa2-1::FUS1-lacZ 
rad16::pGAL1::STE4 
(68)  
TPY1010 (far3) SY2227  far3::kanMX4 This 
study 
Fig. 1A, 
3A 
TPY1013 (far7) SY2227  far7::kanMX4 This 
study 
Fig. 1A, 
3B 
TPY1015 (far8) SY2227  far8::kanMX4 This 
study 
Fig. 1A, 
3C 
TPY1048 (far9) SY2227  far9::kanMX4 This 
study 
Fig. 1A, 
6B 
TPY1072 (far10) SY2227  far10::kanMX4 This 
study 
Fig. 1A 
SY4064 (far11) SY2227  far11::kanMX4 (68) Fig. 1A, 
3D, 5 
SH100 (WT) MATa leu2-3,112 ura3-52 rme1 trp1 his4 
HMLa ade2 tor2::ADE2 [YCplac111::TOR2] 
(57) Fig. 6C 
SH121 (tor2-21) MATa leu2-3,112 ura3-52 rme1 trp1 his4 
HMLa ade2 tor2::ADE2 [YCplac111::tor2-21] 
(57) Fig. 6C 
TPY157 (tor2-21 
far3) 
SH121 far3::kanMX4  (93) Fig. 1B 
TPY147 (tor2-21 
far7) 
SH121 far7::kanMX4  (93) Fig. 1B 
TPY213 (tor2-21 
far8) 
SH121 far8::kanMX4   (93) Fig. 1B 
TPY357 (tor2-21 
far9) 
SH121 far9::kanMX4   (93) Fig. 1B, 
6C-D 
TPY151 (tor2-21 
far10) 
SH121 far10::kanMX4   (93) Fig. 1B 
TPY116 (tor2-21 
far11) 
SH121 far11::kanMX4  (93) Fig. 1B 
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SY4075 (far 
sext) 
SY2227 far3::LEU2 far7::CgTRP1 far8::URA3 
far9::HYGB far10::KAN far11::NAT 
(68)  
TPY845 (far 
sext ura3) 
SY4075 ura3::kanMX4 This 
study 
Fig. 2, 4A, 
4C 
TPY1358 (far3 
far7) 
SY2227  far3::kanMX4 far7::TRP1 [pRS416-
FAR3-GFP] 
This 
study 
Fig. 3A 
TPY1361 (far3 
far8) 
SY2227  far3::kanMX4 far8::TRP1 [pRS416-
FAR3-GFP] 
This 
study 
Fig. 3A 
TPY1348 (far3 
far9) 
SY2227  far3::kanMX4 far9::TRP1 [pRS416-
FAR3-GFP] 
This 
study 
Fig. 3A 
TPY1363 (far3 
far10) 
SY2227  far3::kanMX4 far10::TRP1 [pRS416-
FAR3-GFP] 
This 
study 
Fig. 3A 
TPY1402 (far3 
far11) 
SY2227  far3::kanMX4 far11::TRP1 [pRS416-
FAR3-GFP] 
This 
study 
Fig. 3A 
TPY1408 (far7 
far3) 
SY2227  far7::kanMX4 far3::TRP1 [pRS416-
FAR7-GFP] 
This 
study 
Fig. 3B 
TPY1366 (far7 
far8) 
SY2227  far7::kanMX4 far8::TRP1 [pRS416-
FAR7-GFP] 
This 
study 
Fig. 3B 
TPY1350 (far7 
far9) 
SY2227  far7::kanMX4 far9::TRP1 [pRS416-
FAR7-GFP] 
This 
study 
Fig. 3B 
TPY1368 (far7 
far10) 
SY2227  far7::kanMX4 far10::TRP1 [pRS416-
FAR7-GFP] 
This 
study 
Fig. 3B 
TPY1352 (far7 
far11) 
SY2227  far7::kanMX4 far11::TRP1 [pRS416-
FAR7-GFP] 
This 
study 
Fig. 3B 
TPY1369 (far8 
far3) 
SY2227  far8::kanMX4 far3::TRP1 [pRS416-
FAR8-GFP] 
This 
study 
 
Fig. 3C, 
4B 
TPY1370 (far8 
far7) 
SY2227  far8::kanMX4 far7::TRP1 [pRS416-
FAR8-GFP] 
This 
study 
Fig. 3C, 
4B 
TPY1351 (far8 
far9) 
SY2227  far8::kanMX4 far9::TRP1 [pRS416-
FAR8-GFP] 
This 
study 
Fig. 3C 
TPY1373 (far8 
far10) 
SY2227  far8::kanMX4 far10::TRP1 [pRS416-
FAR8-GFP] 
This 
study 
Fig. 3C 
TPY1405 (far8 
far11) 
SY2227  far8::kanMX4 far11::TRP1 [pRS416-
FAR8-GFP] 
This 
study 
Fig. 3C 
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TPY1374 (far11 
far3) 
SY2227  far11::kanMX4 far3::TRP1 [pRS416-
MKS1-FAR11-GFP] 
This 
study 
Fig. 3D 
TPY1377 (far11 
far7) 
SY2227  far11::kanMX4 far7::TRP1 [pRS416-
MKS1-FAR11-GFP] 
This 
study 
Fig. 3D 
TPY1406 (far11 
far8) 
SY2227  far11::kanMX4 far8::TRP1 [pRS416-
MKS1-FAR11-GFP] 
This 
study 
Fig. 3D 
TPY1410 (far11 
far9) 
SY2227  far11::kanMX4 far9::TRP1 [pRS416-
MKS1-FAR11-GFP] 
This 
study 
Fig. 3D 
TPY1379 (far11 
far10) 
SY2227  far11::kanMX4 far10::TRP1 [pRS416-
MKS1-FAR11-GFP] 
This 
study 
Fig. 3D 
SY4080 (FAR9-
myc) 
SY2227 FAR9-MYC13-KAN [pSL2771, CEN 
LEU2] 
(68)  
TPY1411 
(FAR9-myc) 
SY4080 without the pSL2771 plasmid This 
study 
Fig. 5 
SY4070 (FAR9-
myc far3) 
SY2227 far3::LEU2 FAR9-MYC13-KAN 
[pSL2784, 2µ URA3 FAR3-HA] 
(68)  
TPY1412 (far3 
FAR9-myc) 
SY4070 without the pSL2784 plasmid This 
study 
Fig. 5 
TPY1413 (far7 
FAR9-myc) 
TPY1411 far7::TRP1  This 
study 
Fig. 5 
TPY1416 (far8 
FAR9-myc) 
TPY1411 far8::TRP1 This 
study 
Fig. 5 
TPY1341 
(far9ΔC) 
SH121 far9ΔC This 
study 
Fig. 6C 
 
 
Table 3.  Plasmids used in Chapter 3 
Plasmid Description Source Application 
pTP201 pRS414-SHR3-RFP expressing Shr3 from its own 
promoter with an RFP tag at the C-terminus. 
This 
study 
Fig. 1B 
pTP143 pRS416-FAR3-GFP, expressing Far3 from its own This Fig. 1A-B, 
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promoter with a GFP tag at the C-terminus. study 2, 3A, 4A
pTP164 pRS416-FAR7-GFP, expressing Far7 from its own 
promoter with a GFP tag at the C-terminus. 
This 
study 
Fig. 1A-B, 
2, 3B, 4A 
pTP131 pRS416-FAR8-GFP, expressing Far8 from its own 
promoter with a GFP tag at the C-terminus. 
This 
study 
Fig. 1A-B, 
2, 3C, 4B 
pTP179 pRS416-MKS1-GFP-FAR9, expressing Far9 from the 
MKS1 promoter with a GFP tag at the N-terminus. 
This 
study 
Fig. 1A-B, 
2, 6B, 6D 
pTP203 pRS416-MKS1-GFP-FAR10, expressing Far10 from the 
MKS1 promoter with a GFP tag at the N-terminus. 
This 
study 
Fig. 1A-B, 
2 
pZL2564 pRS416-FAR11-GFP, expressing Far11 from its own 
promoter with a GFP tag at the C-terminus. 
This 
study 
Fig. 1A-B, 
2, 3D 
pTP646 pRS418-FAR7-HA, expressing Far7 from its own 
promoter with a 3xHA tag at the C-terminus. 
This 
study 
Fig. 4A-C 
pTP658 pRS418-FAR8-HA, expressing Far8 from its own 
promoter with a 3xHA tag at the C-terminus. 
This 
study 
Fig. 4A 
pTP655 pRS418-FAR3-HA, expressing Far3 from its own 
promoter with a 3xHA tag at the C-terminus. 
This 
study 
Fig. 4A-C 
pTP664 pRS418-FAR7-FAR3-HA, expressing non-tagged Far7 
from its own promoter and Far3 from its own promoter 
with a 3xHA tag at the C-terminus. 
This 
study 
Fig. 4C 
pTP673 pRS418-FAR3-FAR7-HA, expressing non-tagged Far3 
from its own promoter and Far7 from its own promoter 
with a 3xHA tag at the C-terminus. 
This 
study 
Fig. 4C 
pZL2762 pRS416-FAR11-HA, expressing Far11 from its own 
promoter with a 3xHA tag at the C-terminus.  
(93) Fig. 5 
pTP554 pRS416-MKS1p-GFP-FAR9ΔC, expressing Far9ΔC from 
the MKS1 promoter with a GFP tag at the N-terminus. 
This 
study 
Fig. 6B, 
6D 
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APPENDIX 
 
 
Figure A1. sac7Δ and far11Δ do not suppress the temperature sensitive growth 
phenotype of a tor1Δtor2-21 double mutant.  
Wild-type (SH100), tor1Δ tor2-21 (SH221), tor1Δ tor2-21 sac7Δ (TPY112), and tor1Δ tor2-21 
far11Δ (TPY118) cells were grown on YPD plates at 30 °C and 37 °C.   
 
 
 
 
Figure A2. The effect of rapamycin on the growth of sac7Δ and far11Δ mutant cells.  
Cultures of wild-type (ZLY423), fpr1Δ (TPY122), sac7Δ (ZLY2404), and far11Δ mutant 
(TPY114) cells were serially diluted and spotted on YPD plates supplemented with 
different concentrations of rapamycin.   
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Figure A3. A FAR11-HA fusion construct is functional.  
far11Δ mutant cells (lst8Δ ade2-1 far11Δ, TPY114) carrying plasmid pRS412-LST8 and 
either pRS416 empty vector (Vector) or pRS416-FAR11-HA (FAR11-HA, pZL2762) were 
grown on YNBcasD medium supplemented with adenine.   
 
 
 
 
 
Figure A4. Far11-HA in total cellular proteins prepared by trichloroacetic acid 
precipitation exists as a single band on Western blots.  
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Total cellular proteins were prepared from the yeast strain SY4078 carrying a 
centromeric plasmid encoding FAR11-HA (pZL2762) using the NaOH-β 
mercaptoethanol-trichloroacetic acid method as described (129) and separated by SDS-
PAGE. Far11-HA was detected by immunoblotting with the high affinity rat 
monoclonal anti-HA antibody 3F10 (Roche).   
 
 
 
 
 
 
Figure A5. The effect of far9Δ and far10Δ on suppressing the temperature-sensitive 
growth phenotype of a tor2-21 mutant.  
Wild-type (SH100), tor2-21 (SH121), tor2-21 far9Δ (TPY207), tor2-21 far10Δ (TPY264) and 
tor2-21 far9Δ far10Δ mutant (TPY220) cells were serially diluted and spotted on YPD 
plates and grown at 30 °C and 37 °C.   
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Figure A6. Tetrad analysis of sporulated diploid cells heterozygous for mutations in 
FAR11 and TOR2, AVO1, or AVO3.  
None of the colonies were geneticin (G418) resistant, indicating that no viable tor2Δ, 
avo1Δ, or avo3Δ mutant haploid cells were generated.   
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Figure A7. Tpd3-myc and Pph21-myc are functional.  
(A) Wild type (BY4741) and isogenic tpd3Δ mutant (BY4741 tpd3) cells carrying an 
empty vector (pRS415) or TPD3-myc plasmid (pTP242) as indicated were grown on 
leucine-dropout medium and the picture was taken after 3 days.  
(B) Wild type (BY4741) and isogenic pph21/22Δ mutant (BY4741 pph21/22) cells carrying 
an empty vector (pRS415) or PPH21-myc plasmid (pTP244) were analyzed for cell 
growth as described for panel A.    
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Figure A8. Immunoblot analysis of HA-tagged Ypk2 (A) and Slm2 (B).  
Wild-type (WT, SH100) and temperature-sensitive tor2-21 mutant cells (SH121) 
expressing C-terminal 3xHA-tagged Ypk2 or Slm2 from a centromeric plasmid (YPK2-
HA, pTP271; SLM2-HA, pTP377) were grown in YNBcasD medium at 30 °C to mid-log 
phase and switched to 37 °C for 3h before cellular proteins were processed for Western 
blotting.   
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 Table 1.  Supplemental Strains used in Chapter 2. 
Strain Genotype Source Application 
TPY114 (far11) MATa ade2-1 ura3 his3-11,15 leu2 
lst8::LEU2 far11::kanMX4 [pRS412-
LST8] 
This study Fig, A2, A3 
SY4078 SY2227 FAR7-myc13-KAN 
<pSL2771> 
(68) Fig. A4 
SH100 (WT) MATa leu2-3,112 ura3-52 rme1 trp1 
his4 HMLa ade2 tor2::ADE2 
[YCplac111::TOR2]
(57) Fig. A1, A5, 
A8 
SH121 (tor2-
21) 
MATa leu2-3,112 ura3-52 rme1 trp1 
his4 HMLa ade2 tor2::ADE2 
[YCplac111::tor2-21]
Fig. A5, A8 
SH221 (tor1 
tor2-21) 
MATa leu2-3,112 ura3-52 rme1 trp1 
his3 HMLa ade2 tor1::HIS3 
tor2::ADE2 [YCplac111::tor2-21]
Fig. A1 
TPY110 (tor2-
21 sac7) 
SH121 sac7::kanMX4 This study  
TPY311 (tor2-
21 far11) 
SH121 far11::TRP1 This study  
TPY301 (tor2-
21 sac7 far11) 
SH121 sac7::kanMX4 far11::TRP1 This study  
TPY112 SH221 sac7::kanMX4 This study Fig. A1 
TPY118 SH221 far11::kanMX4 This study Fig. A1 
TPY207 (tor2-
21 far9) 
SH121 far9::kanMX4 This study Fig. A5 
TPY264 (tor2-
21 far10) 
SH121 far10::URA3 This study Fig. A5 
TPY220 (tor2-
21 far9 far10) 
SH121 far9::kanMX4 far10::URA3 This study Fig. A5 
ZLY423 (WT) MATa ade2-1 ura3 his3-11,15 leu2 
lst8::LEU2 [pRS412-LST8]
This study. Fig. A2 
TPY122 (fpr1) MATa ade2-1 ura3 his3-11,15 leu2 
lst8::LEU2 fpr1::kanMX4 [pRS412-
LST8] 
This study Fig. A2 
ZLY2404 
(sac7) 
MATa ade2-1 ura3 his3-11,15 leu2 
lst8::LEU2 sac7::kanMX4 [pRS412-
LST8] 
This study Fig. A2 
TPY114 (far11) MATa ade2-1 ura3 his3-11,15 leu2 
lst8::LEU2 far11::kanMX4 [pRS412-
LST8] 
This study  
  
152 
 
BY4741 
(pph21/22) 
MATa ura3 leu2 his3 met15 
pph21::kanMX4 pph22::kanMX4
This study Fig. A7 
BY4741 MATa ura3 leu2 his3 met15 Yeast 
genome 
deletion 
project 
Fig. A7 
BY4741 tpd3 BY4741 tpd3::kanMX4 Fig. A7 
BY4743 MATa/MATalpha ura3/ura3 leu2/leu2 
his3/his3 lys2/LYS2 met15/MET15 
 
BY4743 
tor2/TOR2 
BY4743 tor2::kanMX4/TOR2  
BY4743 
avo1/AVO1 
BY4743 avo1::kanMX4/AVO1  
BY4743 
avo3/AVO3 
BY4743 avo3::kanMX4/AVO3  
TPY654 BY4743 tor2::kanMX4/TOR2 
far11::HIS3/FAR11 
This study Fig. A6 
TPY652 BY4743 avo1::kanMX4/AVO1 
far11::HIS3/FAR11 
This study Fig. A6 
TPY653 BY4743 avo3::kanMX4/AVO3 
far11::HIS3/FAR11 
This study Fig. A6 
Table 2.  Supplemental Plasmids used in Chapter 2. 
Plasmid Description Source 
pZL2762 pRS416-FAR11-HA, expressing Far11 from its own 
promoter with a 3xHA tag at the C-terminus.  
This study 
pTP377 pRS416-SLM2-HA, expressing Slm2 from its own promoter 
with a 3xHA tag at the C-terminus. 
This study 
pTP271 pRS416-YPK2-HA, expressing Ypk2 from its own promoter 
with a 3xHA tag at the C-terminus. 
This study 
pZL1255 pRS412-LST8 This study 
pTP242 pRS415-ADH1-TPD3-myc, expressing Tpd3 from the 
ADH1 promoter with a 3xmyc tag at the C-terminus. 
This study 
pTP244 pRS415-PPH21-myc, expressing Pph21 from its own 
promoter with a 3xmyc tag at the C-terminus. 
This study 
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